Clinical Trials

The AARS supports clinical investigations by directly funding research through grants and by making available information regarding clinical studies through ClinicalTrials.gov which is a database of privately and publicly funded clinical studies conducted around the world.

Before participating in any clinical studies, check with your health care provider to determine whether proceeding is appropriate for your circumstances. Also, please note that the AARS has not evaluated the studies listed by third party providers. Therefore, to learn more about a study included on the list, please contact the study sponsors directly by following the links provided.

Find A Trial
Showing Results: Any State | Acne | Any Status

[Trial of device that is not approved or cleared by the U.S. FDA]


This is an open-label, single-center clinical trial. The study will involve treatment with
SNA-001 to evaluate subject tolerability and general subject experience with SNA-001
photoparticle therapy for the treatment of facial acne (FA) and unwanted hair (UH) (including
light-pigmented hair)

Condition: Acne Vulgaris, Unwanted Hair | Minimum Age: 12 Years

Status: Withheld | Phase: N/A

First Posted: September 26, 2017 | Last Updated: November 13, 2017

Study Completion Date: January 31, 2019

Learn More

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris


A study for Subjects with mild to moderate facial acne vulgaris. Subjects will be randomized
to treatment with either DFD-03 (tazarotene) Lotion 0.1%, Tazorac (tazarotene) Cream, 0.1%,
Vehicle Lotion or Vehicle Cream. During the 12-week treatment period subjects randomized to
DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to
Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Subjects
will be instructed to treat the entire face.

Safety assessments will include the investigator's assessment of local cutaneous
tolerance/application site reactions on the face, vital signs and adverse events. Urine
pregnancy tests will be performed for all female subjects. A physical examination will be
performed.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Recruiting | Phase: Phase 2

First Posted: October 13, 2017 | Last Updated: November 13, 2017

Study Completion Date: March 01, 2018

Learn More

[Trial of device that is not approved or cleared by the U.S. FDA]


The primary objective of this study is to evaluate the safety and effectiveness of a novel
topical silver particle solution (SIENNA 810.1100) followed by 810 nm laser treatment in the
reduction of inflammatory acne lesions on the face.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Withheld | Phase: N/A

First Posted: October 16, 2015 | Last Updated: November 10, 2017

Study Completion Date: March 01, 2018

Learn More

[Trial of device that is not approved or cleared by the U.S. FDA]


The primary objective of this study is to evaluate the safety and effectiveness of a novel
topical silver particle solution (SIENNA 755.1100) followed by 755 nm laser for treatment of
acne lesions on the face.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Withheld | Phase: N/A

First Posted: June 10, 2016 | Last Updated: November 10, 2017

Study Completion Date: July 01, 2018

Learn More

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa


Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients
suffer from recurring painful abscesses and scarring in their armpits, under the breasts,
groin and other areas of the body. The cause of the disease is still unknown and common
treatments are only sometimes effective. Overactivity of the immune system has been
associated with HS and molecules that cause inflammation have been found in the skin from
people with HS. Current therapies have long-term risks including antibiotic resistance and
the investigators aim to find new safe and effective therapies for HS.

Hydroxychloroquine is a medication that has been used safely in other diseases for many
years. The investigators believe that hydroxychloroquine has the potential to improve HS
through multiple mechanisms. Patients enrolled in this study will be treated with
hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients
with HS to look for inflammatory molecules that we could possibly target for the treatment of
HS. Blood samples will be taken at baseline and following 6 months of treatment.

Condition: Acne Inversa, Boils, Follicular Occlusion Tetrad, Follicular Occlusion Triad, Hidradenitis, Hidradenitis Suppurativa | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 1/Phase 2

First Posted: August 31, 2017 | Last Updated: November 04, 2017

Study Completion Date: June 01, 2019

Learn More

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne


The study is designed primarily to assess preliminary efficacy and safety of CJM112 in
patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate
clinical profile for further clinical development. In addition, sustainability of response
and dose relationship will be explored.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 2

First Posted: December 13, 2016 | Last Updated: November 03, 2017

Study Completion Date: January 10, 2019

Learn More

Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT


This study is examining the effects of the 2940 nm Er:YAG on atrophic facial acne scars under
optical coherence tomography in terms of blood flow, vessel shape, skin roughness, collagen
content, and epidermal thickness.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Not yet recruiting | Phase: N/A

First Posted: August 01, 2017 | Last Updated: November 03, 2017

Study Completion Date: December 01, 2018

Learn More

Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris


The purpose of this research study is to evaluate the effectiveness of two different types of
topical acne medication. This study will help to determine if one combined medication results
in better acne improvement than two separate medications for acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: January 11, 2010 | Last Updated: November 01, 2017

Study Completion Date: October 01, 2009

Learn More

Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris


The purpose of the study is to evaluate the efficacy of facial acne vulgaris treatment using
the Venus Versa Diamondpolar applicator in combination with the Venus Versa AC dual
applicator using two intense pulsed light wavelength bands.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: September 30, 2016 | Last Updated: November 01, 2017

Study Completion Date: January 01, 2018

Learn More

A Treatment for Severe Inflammatory Acne Subjects


Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral
Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules
or cysts (non-nodulocystic) during a 12-week treatment period.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: September 08, 2016 | Last Updated: October 30, 2017

Study Completion Date: June 27, 2017

Learn More

Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris


Prospective, randomized, controlled, parallel group clinical study with blinded assessment
evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Recruiting | Phase: N/A

First Posted: October 02, 2017 | Last Updated: October 26, 2017

Study Completion Date: July 01, 2018

Learn More

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)


The primary objective of this study is to determine the safety and efficacy of CB-03-01
cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: November 17, 2015 | Last Updated: October 24, 2017

Study Completion Date: March 01, 2018

Learn More

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)


The primary objective of this study is to determine the safety and efficacy of CB-03-01
cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: November 17, 2015 | Last Updated: October 24, 2017

Study Completion Date: March 01, 2018

Learn More

Cultural Differences in Treatment Preferences and Perceptions of Acne


This study will use a survey to examine relationships between culture, race, and ethnicity
with treatment preferences and perceptions for acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: June 15, 2017 | Last Updated: October 23, 2017

Study Completion Date: October 01, 2017

Learn More

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris


UHE-101 cream, 1% ("UHE-101") is being developed for the topical treatment of acne vulgaris.
The purpose of this study is to compare the safety and efficacy of twice daily topical
application of UHE-101 cream for 12 weeks to its vehicle cream in subjects with facial acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Recruiting | Phase: Phase 2

First Posted: October 05, 2017 | Last Updated: October 10, 2017

Study Completion Date: October 01, 2018

Learn More

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris


The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil
Gel compared to vehicle in patients with acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: March 03, 2017 | Last Updated: October 06, 2017

Study Completion Date: March 01, 2018

Learn More

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris


The objectives of this study are to assess the long-term safety of Olumacostat Glasaretil
gel, 5.0% in patients with acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: April 17, 2017 | Last Updated: October 06, 2017

Study Completion Date: March 01, 2019

Learn More

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris


The purpose of this study is to evaluate the superiority in efficacy and assess safety and
tolerability of the products S6G5T-3 and S6G5T-1 as compared to their respective active
components or the vehicle for the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 2

First Posted: January 11, 2016 | Last Updated: October 03, 2017

Study Completion Date: October 01, 2017

Learn More

SkinPen Efficacy on Acne Scars on the Face and/or Back


This single-center, clinical trial will take place over a 90 day course followed by 1-month
and 6-month post treatment visits to assess the efficacy and tolerability of the SkinPen
device when used on both men and women on the face and/or back.

Condition: Atrophic Acne Scar | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: December 21, 2015 | Last Updated: September 29, 2017

Study Completion Date: July 25, 2017

Learn More

A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars


This is an open-label, randomized, multicenter, prospective trial assessing the efficacy and
safety of microneedling treatment alone vs. microneedling treatment followed by treatment
with Bellafill for correction of distensible atrophic facial acne scars.

Condition: Atrophic Acne Scars | Minimum Age: 21 Years

Status: Completed | Phase: N/A

First Posted: December 29, 2015 | Last Updated: September 27, 2017

Study Completion Date: June 01, 2017

Learn More

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks


Enrollment of subjects with mild to moderate facial acne vulgaris. Acne lesions of any
severity on the chest and/or back (including shoulders) may be enrolled provided they have
mild to moderate acne on the face. During the 12-week treatment period subjects will use the
study product twice daily with approximately 12 hours between applications. Subjects will be
instructed to treat the entire face (and chest/back including shoulders, if applicable).

Co-Primary efficacy endpoints include:

- Absolute change from Baseline to Week 12 in the inflammatory lesion counts on the face

- Absolute change from Baseline to Week 12 in the non-inflammatory lesion counts on the
face

- Proportion of subjects with a clinical response of "success" at Week 12 for lesions on
the face. Success based on IGA is defined as an IGA score of 0 (Clear) or 1 (Almost
clear) at Week 12 with at least a 2-grade reduction from Baseline.

The primary safety endpoint will be treatment-emergent adverse events (TEAEs). Other safety
variables include local cutaneous tolerance evaluation (dryness, non-lesional erythema,
peeling, stinging, burning, and itching) and vital signs (blood pressure and pulse rate).
Urine pregnancy tests will be performed at Baseline and at every visit through Week 12 for
all female subjects. A physical examination will be performed at the Baseline Visit.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: September 21, 2017 | Last Updated: September 22, 2017

Study Completion Date: March 01, 2018

Learn More

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel


Study designed to assess the safety and plasma PK of tretinoin and its metabolites from
topically applied IDP-120 gel.

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 1

First Posted: July 06, 2016 | Last Updated: September 20, 2017

Study Completion Date: November 01, 2016

Learn More

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris


Enrollment of subjects with mild to moderate facial acne. Subjects with acne lesions of any
severity on the chest and/or back (including shoulders) may be enrolled provided they have
mild to moderate acne on the face. During the 12-week treatment period subjects will use the
study product twice daily. Subjects will be instructed to treat the entire face (and chest
and/or back including shoulders, if applicable).

Efficacy will be assessed by using an Investigator's Global Assessment scale (IGA 5 point
scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at
Baseline and Weeks 4, 8, and 12.

Safety assessments will include the investigator's assessment of local cutaneous tolerance of
the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching;
assessed separately on the chest and/or back including shoulders (if applicable), vital signs
(blood pressure and pulse rate), and adverse events (AEs). Urine pregnancy tests will be
performed at Baseline and at every visit through Week 12 for all female subjects. A physical
examination will be performed.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: September 19, 2017 | Last Updated: September 19, 2017

Study Completion Date: February 01, 2018

Learn More

Multi-center, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study in the Treatment of Acne Vulgaris


This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed
to assess the safety, efficacy, and tolerability of IDP-123 Lotion and IDP-123Vehicle Lotion.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: May 24, 2017 | Last Updated: September 15, 2017

Study Completion Date: July 30, 2018

Learn More

Effect of Subcision and Suction on Acne Scars


The primary objective of this study is to determine whether the use of standard treatment in
conjunction with suction will improve acne scars compared to a standard treatment alone.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Active, not recruiting | Phase: N/A

First Posted: September 14, 2012 | Last Updated: September 13, 2017

Study Completion Date: September 01, 2018

Learn More

Safety Study of Plasma Treatment System to Treat Back Acne


The purpose of this study is to evaluate the safety of treating human skin with atmospheric
plasma and get an initial evaluation of the efficacy of this treatment for acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Terminated | Phase: N/A

First Posted: August 02, 2012 | Last Updated: September 12, 2017

Study Completion Date: June 01, 2013

Learn More

Topical Treatment and Prevalence of P. Acnes


This study is about preventing surgical site infections of the shoulder. We hope to learn if
clindamycin alone, benzoyl peroxide alone, or clindamycin and benzoyl peroxide together can
affect growth of Propionibacterium acnes in the dermal layer.

Condition: Surgical Site Infection | Minimum Age: 18 Years

Status: Enrolling by invitation | Phase: Phase 2

First Posted: August 01, 2017 | Last Updated: September 12, 2017

Study Completion Date: November 01, 2017

Learn More

enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars


The purpose of this pivotal investigation is to evaluate the efficacy and safety of the
Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser
and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne
scars.

Condition: Acne Scars - Mixed Atrophic and Hypertrophic | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: September 11, 2017 | Last Updated: September 12, 2017

Study Completion Date: September 01, 2018

Learn More

CD5789 Long Term Safety Study on Acne Vulgaris


Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of
treatment on the face and trunk for acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: July 11, 2014 | Last Updated: September 11, 2017

Study Completion Date: February 23, 2017

Learn More

Comparison of Two Salicylic Acid Formulations


This study is a split face, paired-comparison, pilot study of at least 10 subjects to
complete. Participants in this study will be patients seen at Children's Memorial Hospital,
who are clinically diagnosed with mild to moderate acne vulgaris. Participants will be
recruited from one of the clinics, as well as from previous Institutional Review Board (IRB)
approved acne studies housed in the Department of Dermatology. All subjects accrued from
previous studies have agreed to be contacted for further investigations. Subjects 13 to 35
years of age with mild to moderate acne vulgaris symmetrical in appearance on both sides of
the face, and meeting inclusion criteria will be eligible to participate

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: N/A

First Posted: November 24, 2008 | Last Updated: September 08, 2017

Study Completion Date: August 01, 2008

Learn More

Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris


Prospective, randomized multicenter study to examine the safety and effectiveness of Sebacia
microparticles with or without laser in the treatment of moderate to moderately-severe
inflammatory acne vulgaris

Condition: Inflammatory Acne Vulgaris | Minimum Age: 15 Years

Status: Completed | Phase: N/A

First Posted: August 11, 2014 | Last Updated: September 08, 2017

Study Completion Date: December 01, 2015

Learn More

An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris


The primary objective of this study is to determine the long-term safety of CB-03-01 cream,
1% applied twice daily for an additional nine months in study participants with acne vulgaris
that participated in the Phase 3 pivotal studies for a total treatment of up to 12 months.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Enrolling by invitation | Phase: Phase 3

First Posted: February 10, 2016 | Last Updated: September 06, 2017

Study Completion Date: December 01, 2018

Learn More

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris


The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil
Gel compared to vehicle in patients with acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: January 19, 2017 | Last Updated: September 05, 2017

Study Completion Date: March 01, 2018

Learn More

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA


This study evaluates the safety, effectiveness, and maintenance of effect of a novel topical
silver particle solution (Sienna 755.1100, 810.1100, or 1064.1100) used in conjunction with a
laser for the treatment of Acne Vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: January 25, 2017 | Last Updated: September 05, 2017

Study Completion Date: July 01, 2018

Learn More

Double-Blind Efficacy and Safety of CD5789 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris


Assessment of the efficacy and safety of CD5789 50µg/g cream applied once daily for 12 weeks
in subjects with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: September 18, 2015 | Last Updated: August 31, 2017

Study Completion Date: May 12, 2017

Learn More

Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris


Assessment of the efficacy and safety of CD5789 50μg/g cream applied once daily for 12 weeks
in subjects with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: October 01, 2015 | Last Updated: August 31, 2017

Study Completion Date: January 01, 2018

Learn More

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris


A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of
Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne
Vulgaris (Study FX2017-22)

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: August 30, 2017 | Last Updated: August 31, 2017

Study Completion Date: September 03, 2018

Learn More

ABSORICA in Patients With Severe Recalcitrant Nodular Acne


This is an uncontrolled, open-label study being conducted in approximately 200 healthy males,
non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.

ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by
1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or
abstinence are included.

Condition: Acne | Minimum Age: 12 Years

Status: Active, not recruiting | Phase: Phase 4

First Posted: May 16, 2015 | Last Updated: August 29, 2017

Study Completion Date: November 01, 2017

Learn More

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris


The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream
formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the
treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: November 13, 2007 | Last Updated: August 28, 2017

Study Completion Date: January 01, 2008

Learn More

Wound Etiology and Healing Study


The purpose of the WE-HEAL Study is to help researchers use human tissue samples and health
records to study the reasons why some patients heal quickly and some have problems healing
wounds. All patients seen with an open wound or hidradenitis suppurativa are invited to
participate. Information from this research may help to understand how to prevent and treat
certain diseases.

Condition: Acne Inversa, Hidradenitis, Hidradenitis Suppurativa, Wounds | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: May 10, 2011 | Last Updated: August 28, 2017

Study Completion Date: June 01, 2021

Learn More

Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.


To assess facial acne vulgaris clinical and psychological outcomes by measuring differences
in lesions counts, investigator global assessment, and subjects quality of life scores over 6
months in adult females treated with Next Science™ acne cream 2x or Next Science™ acne cream
1x in a double blind manner.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Terminated | Phase: Early Phase 1

First Posted: March 27, 2017 | Last Updated: August 28, 2017

Study Completion Date: August 14, 2017

Learn More

Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment


The goal of this study is to enroll 250 participants that have joined the MURDOCK Study
Horizon 1.5 (Duke IRB Pro00011196) with a current or prior diagnosis of severe acne AND
current or prior treatment with oral isotretinoin. All 250 participants will answer a 5-page
questionnaire designed to collect information on the diagnosis of severe acne and response to
oral isotretinoin treatment. The aim is to identify genetic predictors of severe acne
vulgaris and the outcome of oral isotretinoin treatment.

Condition: Acne Vulgaris, Isotretinoin | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: October 24, 2012 | Last Updated: August 23, 2017

Study Completion Date: August 01, 2015

Learn More

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne


This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical
administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: May 24, 2016 | Last Updated: August 22, 2017

Study Completion Date: November 01, 2017

Learn More

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne


This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical
administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: May 24, 2016 | Last Updated: August 22, 2017

Study Completion Date: November 01, 2017

Learn More

Propionibacterium Acnes in Shoulder Arthroplasty


The investigator's plan to determine whether pre-operative skin preparation with hydrogen
peroxide alters rates of P acnes culture positivity. They hypothesize that pre-operative skin
preparation with hydrogen peroxide will reduce rates of P acnes culture positivity.

Condition: Propionibacterium Acnes | Minimum Age: 40 Years

Status: Enrolling by invitation | Phase: N/A

First Posted: February 14, 2017 | Last Updated: August 21, 2017

Study Completion Date: January 01, 2020

Learn More

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline


The primary objective of this study is to evaluate the skin and plasma concentrations of
minocycline in subjects undergoing treatment of acne vulgaris with oral extended release
minocycline. Acne lesion counts and safety/tolerance of the treatment will also be evaluated.

Condition: Acne | Minimum Age: 14 Years

Status: Completed | Phase: Phase 4

First Posted: February 18, 2016 | Last Updated: August 16, 2017

Study Completion Date: May 01, 2016

Learn More

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes


This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate
the comparative reduction of Propionibacterium acnes in-vivo following once daily topical
administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: March 10, 2016 | Last Updated: August 16, 2017

Study Completion Date: June 01, 2016

Learn More

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study in the Treatment of Acne Vulgaris


This is a multicenter, randomized, double-blind, vehicle-controlled study designed to assess
the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle
Lotion.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 3

First Posted: May 24, 2017 | Last Updated: August 11, 2017

Study Completion Date: July 30, 2018

Learn More

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris


A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing
Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a
Vehicle Control in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: August 29, 2016 | Last Updated: August 08, 2017

Study Completion Date: May 22, 2017

Learn More

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments


The purpose of this study is to evaluate the efficacy of 2 acne treatments for 24 weeks of
use in adult men and women with mild to moderate facial acne, at least 5 inflammatory
lesions, and at least 10 - 100 non-inflammatory lesions.

Objective:

1. To characterize the effectiveness of the acne treatment in lesion count at week 1, week
2, week 6, week 12, and week 24 as compared to baseline and compare between treatments

2. To characterize the effectiveness of the acne treatment in Investigator's Global
Improvement Assessment at week 1, week 2, week 6, week 12, and week 24 as compared to
baseline and compare between treatments

3. To characterize the effect of the acne treatment in clinical grading of efficacy
parameters through digital images at week 6, week 12, and week 24 as compared to
baseline and compare between treatments

4. To characterize the effect of the acne treatment in subject self-assessment
questionnaire responses at week 1, week 2, week 6, week 12, and week 24 as compared to
baseline and compare between treatments

Condition: Acne | Minimum Age: 21 Years

Status: Completed | Phase: Phase 4

First Posted: April 18, 2016 | Last Updated: July 31, 2017

Study Completion Date: April 04, 2017

Learn More

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris


The objective of the study is to compare the safety and efficacy of multiple formulations of
BLI1100 to a control group and placebo in treating patients with moderate-severe acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: November 12, 2015 | Last Updated: July 27, 2017

Study Completion Date: June 01, 2016

Learn More

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris


Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 2

First Posted: May 06, 2016 | Last Updated: July 24, 2017

Study Completion Date: September 30, 2016

Learn More

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris


The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244
administered over 12 weeks to participants with mild to moderate acne vulgaris relative to
placebo.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2/Phase 3

First Posted: July 08, 2016 | Last Updated: July 20, 2017

Study Completion Date: July 19, 2017

Learn More

Finasteride Treatment of Severe Nodulocystic Acne


Double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and
safety of once weekly, high dose oral finasteride compared to placebo for the treatment of
severe nodulocystic acne in male subjects.

Condition: NODULOCYSTIC ACNE | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: July 10, 2015 | Last Updated: July 19, 2017

Study Completion Date: June 06, 2017

Learn More

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel


This is a single center open label study intended to provide photo documentation and time to
response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to
severe non-nodular inflammatory acne vulgarism.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 2

First Posted: October 25, 2016 | Last Updated: July 18, 2017

Study Completion Date: December 01, 2017

Learn More

Potential Research Study Participant Registry


The purpose of the potential research study participant registry is to keep potential
research subjects informed about any future research studies in which they may meet the
criteria for enrollment. The purpose of this study is also to assist current and future
clinical trials with recruitment of subjects.

Condition: Acne, Actinic Keratosis, Atopic Dermatitis, Dysplastic Nevi, Eczema, Foot Ulcers, Leg Ulcers, Psoriasis, Rosacea, Skin Cancer | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: July 02, 2008 | Last Updated: July 17, 2017

Study Completion Date: January 01, 2025

Learn More

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris


The study will look to evaluate the tolerance of a light therapy-based acne mask device in
participants who report having sensitive skin. All participants will receive a cleanser, a
light therapy mask, and an extra activator for the light therapy mask.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: April 20, 2017 | Last Updated: July 17, 2017

Study Completion Date: June 08, 2017

Learn More

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris


This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of
ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 4

First Posted: November 07, 2016 | Last Updated: July 06, 2017

Study Completion Date: March 24, 2019

Learn More

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris


The purpose of this study is to assess systemic exposure of a new foam formulation of
tazarotene, 0.1% compared with Tazorac Gel, 0.1%. The study design and dosing regimen are
based on previous clinical studies with Tazorac Gel and Tazorac Cream.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 1

First Posted: November 19, 2009 | Last Updated: June 22, 2017

Study Completion Date: December 20, 2009

Learn More

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers


The purpose of this study is to evaluate the irritation level of tazarotene foam after 21
days of exposure on the skin of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: April 27, 2010 | Last Updated: June 19, 2017

Study Completion Date: April 26, 2010

Learn More

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers


The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a
phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: April 30, 2010 | Last Updated: June 19, 2017

Study Completion Date: April 10, 2010

Learn More

De Novo Lipogenesis of Sebaceous Glands in Acne


There are two purposes of this study:

1. First, the investigators want to see what the differences are in de novo sebaceous lipid
production of people with and without acne.

2. Secondly, the investigators want to know what happens to sebaceous gland de novo lipid
production before and after treatment with topical tretinoin and oral isotretinoin.

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Recruiting | Phase: Phase 4

First Posted: December 01, 2015 | Last Updated: June 19, 2017

Study Completion Date: May 01, 2019

Learn More

A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers


This study will assess the potential of tazarotene foam to cause sensitization during a 48
hour challenge following 21 days of exposure on the skin of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: April 29, 2010 | Last Updated: June 12, 2017

Study Completion Date: June 26, 2010

Learn More

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.


The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a
photoallergic reaction when exposed to UV and VIS light on skin of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: May 05, 2010 | Last Updated: June 12, 2017

Study Completion Date: June 26, 2010

Learn More

DMT210 Topical Gel in the Treatment of Acne Rosacea


The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied
twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of
participants will receive DMT210 Gel while the other half will receive vehicle control.

Condition: Acne Rosacea | Minimum Age: 18 Years

Status: Active, not recruiting | Phase: Phase 2

First Posted: December 20, 2016 | Last Updated: June 07, 2017

Study Completion Date: September 01, 2017

Learn More

Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne


The purpose of this research study is to see how often benzoyl peroxide is applied for acne.
Use of medication was monitored electronically.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: Phase 4

First Posted: April 09, 2008 | Last Updated: June 06, 2017

Study Completion Date: May 01, 2008

Learn More

To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.


This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study,
designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5%
topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel,
Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: June 04, 2015 | Last Updated: May 26, 2017

Study Completion Date: December 01, 2015

Learn More

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel


The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in
subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel,
Tretinoin Gel and Vehicle Gel for the treatment of acne vulgaris.

Condition: Acne, Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: May 24, 2008 | Last Updated: May 25, 2017

Study Completion Date: May 01, 2009

Learn More

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications


This is a randomized, half-face study. On 1 side of the face, the subject will apply 1 of the
2 test products, clindamycin and benzoyl peroxide or dapsone gel and the contra lateral side
of the face will remain non-treated to serve as a control.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: August 20, 2009 | Last Updated: May 25, 2017

Study Completion Date: August 01, 2009

Learn More

The Lipid Profile of the Skin Surface in Acne


The purpose of this study is to evaluate the differences in the skin lipid profile of
patients with and without acne. Secondly, the goal is to learn more about what the effects of
retinoinds (topical and systemic) are on the the skin lipid profile. We hypothesize that the
skin lipid profile of subjects with acne will be lower in inflammatory lipids in comparison
to subjects without acne.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: June 30, 2014 | Last Updated: May 25, 2017

Study Completion Date: July 01, 2015

Learn More

Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne


To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin
vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of
moderate acne

Condition: Acne | Minimum Age: 16 Years

Status: Completed | Phase: Phase 4

First Posted: February 04, 2009 | Last Updated: May 24, 2017

Study Completion Date: August 01, 2008

Learn More

Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne


The purpose of the study is to determine the development of microbial resistance when using
one of two topical acne therapies for the treatment of facial acne vulgaris.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: February 10, 2009 | Last Updated: May 24, 2017

Study Completion Date: January 01, 2009

Learn More

Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris


To see if teledermatology can be used to reduce antibiotic burden in patients on doxycycline
or minocycline for acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Recruiting | Phase: N/A

First Posted: June 09, 2016 | Last Updated: May 24, 2017

Study Completion Date: May 01, 2018

Learn More

A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash


The purpose of this study is to evaluate the tolerability of a combined regimen of a topical
antibiotic and retinoid and a benzoyl peroxide wash.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: April 29, 2009 | Last Updated: May 19, 2017

Study Completion Date: June 05, 2009

Learn More

The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area


This is an open-label, multicenter, prospective pilot study assessing the efficacy and safety
of Bellafill for correction of distensible atrophic acne scars in the full facial area. All
enrolled subjects will receive initial treatment with Bellafill, as well as touch-up
treatments (if necessary to achieve optimal correction). Subjects will be evaluated at
Screening (Month -1), Day 0 (Baseline) Month 1, Month 4, and Month 7.

Condition: Atrophic Acne Scarring | Minimum Age: 21 Years

Status: Completed | Phase: N/A

First Posted: December 28, 2015 | Last Updated: May 09, 2017

Study Completion Date: January 30, 2017

Learn More

Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne


An exploratory Phase 2, single, centre, prospective, randomized, placebo-controlled,
double-blinded, split-pace (left/right) design trial to evaluate the efficacy and
tolerability of LEO 43204 in adults with moderate to severe acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: October 13, 2015 | Last Updated: May 04, 2017

Study Completion Date: April 01, 2017

Learn More

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders


This study examines the efficacy of a non-thermal, atmospheric plasma device in the treatment
of a number of different skin disorders

Condition: Acne, Actinic Keratosis, Tinea, Verruca Plana | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: April 26, 2016 | Last Updated: April 27, 2017

Study Completion Date: December 31, 1969

Learn More

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris


Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 1

First Posted: October 11, 2016 | Last Updated: April 26, 2017

Study Completion Date: March 20, 2017

Learn More

Efficacy and Safety of IDP-121 Lotion and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris


Efficacy and Safety of IDP-121 Lotion and IDP-121 Vehicle Lotion in the Treatment of Acne
Vulgaris

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: October 11, 2016 | Last Updated: April 26, 2017

Study Completion Date: April 12, 2017

Learn More

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris


The purpose of this study is to determine the safety and effectiveness of TSN 2898 topical
gel in the treatment of moderate to severe acne.

Condition: Acne Vulgaris | Minimum Age: 16 Years

Status: Withdrawn | Phase: Phase 2

First Posted: May 26, 2016 | Last Updated: April 24, 2017

Study Completion Date: February 01, 2017

Learn More

Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream


The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac
Cream.

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 1

First Posted: July 06, 2016 | Last Updated: April 24, 2017

Study Completion Date: January 01, 2017

Learn More

Restylane Silk Acne Scar Efficacy Evaluation Study


Randomized, double-blind, placebo-controlled, research pilot study. 30 subjects aged 22-55
years old of all skin types will be asked to sign an informed consent form prior to any study
procedures. Subjects must have at least 1 but up to 3 acne scars ≥3 mm or ≤ 10 mm located on
the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk or Placebo) in
each scar at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will
be asked to come to 10 visits: Screening visit (up to 35 days prior to Baseline), Baseline
(Day 0), Day 7, Day 14, Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6 (study exit
visit). The treatment area will be evaluated at each visit by the unblinded investigator
regarding erythema, bruising, inflammation, itching, stinging/burning, brightness, fullness,
smoothness, and clarity. Safety and adverse events will be captured at each visit only by the
unblinded investigator.

Condition: Acne, Acne Scars, AdverseEvent | Minimum Age: 22 Years

Status: Recruiting | Phase: N/A

First Posted: November 02, 2016 | Last Updated: April 24, 2017

Study Completion Date: August 01, 2018

Learn More

U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, Salicylic Acid 0.5%) in Subjects With Acne


This study is being conducted to obtain safety, efficacy, and satisfaction data on the
combination of topical Benzoyl Peroxide (BPO) 2.5% and the topical keratolytic agent
Salicylic Acid (SA) 0.5% in the treatment of moderate to severe acne. Subjects with moderate
or severe acne will be asked to apply the commercially available, over-the-counter products
Foam Deep Cleanser (2.5% BPO), Foam Advanced Acne Treatment (2.5% BPO), and Foam Rejuvenating
Toner (0.5% SA) daily for 12 weeks. No control group or reference treatment will be included.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: July 28, 2011 | Last Updated: April 21, 2017

Study Completion Date: December 15, 2011

Learn More

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne


The purpose of this study is to assess safety and efficacy of a new foam formulation of
tazarotene in subjects with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: November 19, 2009 | Last Updated: April 17, 2017

Study Completion Date: November 09, 2010

Learn More

Effect of Samples on Acne Treatment With Epiduo® Gel


The purpose of this study is to compare adherence to treatment and efficacy with Epiduo® Gel
in patients with mild to moderate acne who receive a medication sample and instructions on
proper application with their stock size medication tube versus patients who receive only the
stock size medication tube.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: December 28, 2011 | Last Updated: April 17, 2017

Study Completion Date: November 01, 2012

Learn More

Lipidome and Microbiome Profile of Acne


Lipidome and microbiome analysis in subjects with acne on doxycycline. Investigators will
look at the skin lipidome, blood lipidome, gut micro biome and skin micro biome.

Investigators will look at the changes between acne subjects and control participants, but
also the changes that occur after the use of antibiotics and how this is altered.

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Active, not recruiting | Phase: Phase 1/Phase 2

First Posted: March 02, 2016 | Last Updated: April 17, 2017

Study Completion Date: February 01, 2018

Learn More

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide


The study team plans to enroll a total of 40 subjects with self-reported perimenstrual acne.
Eligible women will be over the age of 18 and not on any current therapy. The patients will
first arrive for a screening visit, where they will be given questionnaires on acne quality
of life (acne QOL) and subjective assessments as well as flare ups (as used in the study by
Geller et al). The patients' skin will be assessed for inflammatory and non-inflammatory acne
vulgaris. The baseline visit (day 1) will be scheduled for one week prior to the first day of
menses (as studies indicate that most women have their acne flare during this time). The
study team will perform a zit count (counting papules, pustules, and comedones) and global
assessment, and the patient will be instructed to record their menses (which they will do for
the duration of the study). The patients will then return in 2 weeks, at day 15, and they
will be re-assessed. The patients will be dispensed the investigational product and
instructed on its daily use. The patients will continue to return every 14 days to have their
skin assessed until their final visit on day 99, one week after their 3rd menses on treatment
(4th menses on study). The duration of the study per patient is approximately 4 months, and
the study team anticipates an enrollment period of 12 months.

Condition: Actinic Keratosis | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 2

First Posted: April 17, 2017 | Last Updated: April 17, 2017

Study Completion Date: January 01, 2019

Learn More

A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.


This study will compare two different acne treatments for the treatment of acne. Half of the
participants will receive two marketed acne products (cleanser and leave-on topical
treatment), while the other half of the participants will receive a marketed cleanser and a
light-therapy device.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: February 26, 2016 | Last Updated: April 12, 2017

Study Completion Date: August 16, 2016

Learn More

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris


This is a 12-week, multi-center, double-blind, randomized, three-arm, vehicle-controlled
study.

Subjects will be randomized (1:1:1) to 1% or 2 % BPX-01 gel, or vehicle. Subjects will apply
1g of the gel as a thin film to the entire face at least 30 minutes before bedtime each night
for 12 weeks. Lesion counts, IGA, and Patient-Reported Outcomes (PGI-S and PGI-I) will be
performed to assess efficacy.

Blood draws will be collected at baseline (Day 0), and at Weeks 4 and 12 to evaluate the
level of minocycline in plasma. Safety will be assessed with the vital signs, brief physical
examination, clinical laboratory tests, cutaneous tolerance score, incidence of
minocycline-induced skin hyperpigmentation, incidence of visual disturbances and/or headaches
suggestive of pseudotumor cerebri, and collection of adverse events.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 2

First Posted: June 24, 2016 | Last Updated: April 12, 2017

Study Completion Date: March 24, 2017

Learn More

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption


This randomized, controlled, phase II clinical study is designed to assess the efficacy of
preemptive treatment with topical steroids in preventing the papulopustular eruption induced
by epidermal growth factor receptor inhibitor (EGFRI) treatment in cancer patients.
Participants will be followed up for 6 weeks of twice daily application of triamcinolone
cream to the face, chest, and back.

Condition: Acneiform Rash, Papulopustular Eruption | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 2

First Posted: February 15, 2017 | Last Updated: April 11, 2017

Study Completion Date: January 01, 2018

Learn More

Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?


The purpose of this study is to investigate antibiotic treatment to target bacteria about the
shoulder. This bacteria, Propionibacterium acnes, is detected in many revision shoulder
surgeries and is thought to contribute to periprosthetic joint infections, pain, and failure
of total shoulder arthroplasty as well as other shoulder surgeries. This study is
investigating adding an FDA approved antibiotic that is commonly used for treatment of this
bacteria and many common infections. The investigators will take intraoperative cultures to
look for the presence or absence of specific bacteria. The investigators are conducting this
trial to see if adding another antibiotic to specifically target this common bacteria found
around the shoulder will be effective.

Condition: Osteoarthritis | Minimum Age: 40 Years

Status: Completed | Phase: N/A

First Posted: April 25, 2016 | Last Updated: April 10, 2017

Study Completion Date: February 01, 2017

Learn More

Sebum Collection and Skin Barrier Function Analysis


The goal is this study is to evaluate how the skin surface lipid composition is correlated
with overall sebum production, barrier function, and inflammatory disease status. We
hypothesize that there will be differences in the skin surface composition among subjects of
various groups:

1. Young vs older healthy population

2. Atopic dermatitis vs Acne vs Healthy controls

3. Active smokers vs non-smoker controls

Condition: Acne, Aging, Atopic Dermatitis, Smoking | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: July 10, 2014 | Last Updated: April 07, 2017

Study Completion Date: February 26, 2016

Learn More

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris


This is a single center, randomized, double-blind, placebo-controlled study in subjects with
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: January 11, 2016 | Last Updated: April 03, 2017

Study Completion Date: July 15, 2016

Learn More

A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne


This is a 12 week, multi-site, double-blind, vehicle-controlled study in subjects with mild
to moderate facial acne. Subjects will be randomized 1:1 to apply either topical NAG or
vehicle gel daily. Subjects will be evaluated for clinical acne and quality of life outcomes
at baseline, 2 weeks, 4 weeks, 8 weeks and 12 weeks.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: March 13, 2015 | Last Updated: March 27, 2017

Study Completion Date: September 01, 2015

Learn More

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris


The primary objective of this study is to evaluate the safety and efficacy of Omiganan
(CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in
female subjects with moderate to severe inflammatory acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: October 02, 2015 | Last Updated: March 24, 2017

Study Completion Date: August 01, 2016

Learn More

Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications


This is a single-blind (blinded expert grader) study that will enroll 25-30 healthy
volunteers without facial acne. On 1 side of the face, the subject will apply 1 of the 2 test
products, clindamycin and benzoyl peroxide 5% or clindamycin phosphate and benzoyl peroxide
2.5% and the other side of the face will remain non-treated to serve as a control.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: November 17, 2009 | Last Updated: March 21, 2017

Study Completion Date: September 01, 2009

Learn More

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients


This is a randomized, double blind, multicenter study in patients with moderate to severe
chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of
multiple doses of CJM112 in comparison to placebo. The study has two periods to explore
preliminary dose effects.

Condition: Hidradenitis Suppurativa (Acne Inversa) | Minimum Age: Years

Status: Completed | Phase: Phase 2

First Posted: March 18, 2015 | Last Updated: March 14, 2017

Study Completion Date: November 23, 2016

Learn More

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy


This study is being done to evaluate the effect of targeted UV-B (a component of sunlight) on
the treatment of acne keloidalis nuchae (AKN, or razor bumps on the back of the neck). The
investigators believe targeted UV-B is a safe and effective way to reduce the appearance of
AKN.

Condition: Acne Keloidalis Nuchae | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: March 31, 2011 | Last Updated: February 28, 2017

Study Completion Date: August 01, 2012

Learn More

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris


Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral
sarecycline in the long-term treatment of subjects with moderate to severe facial acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: April 02, 2015 | Last Updated: February 23, 2017

Study Completion Date: August 01, 2016

Learn More

Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars


Open-label, prospective study. Up to 60 healthy adult volunteers seeking facial acne scars
treatment, males or females of 18 to 75 years of age, from up to 3 investigational sites.

Condition: Acne Scars - Mixed Atrophic and Hypertrophic | Minimum Age: 18 Years

Status: Active, not recruiting | Phase: N/A

First Posted: October 28, 2015 | Last Updated: February 22, 2017

Study Completion Date: August 01, 2017

Learn More

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne


To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline
compared to placebo in the treatment of moderate to severe facial acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: December 15, 2014 | Last Updated: February 15, 2017

Study Completion Date: February 01, 2017

Learn More

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne


To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline
compared to placebo in the treatment of moderate to severe facial acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 3

First Posted: December 15, 2014 | Last Updated: February 15, 2017

Study Completion Date: January 01, 2016

Learn More

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris


This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression
potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve
hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris.
Adrenal suppression effects and systemic safety are an important safety concern. The current
study is designed to investigate these potential concerns under maximal use conditions.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Recruiting | Phase: Phase 2

First Posted: March 22, 2016 | Last Updated: February 15, 2017

Study Completion Date: December 01, 2017

Learn More

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris


The primary objective of this study is to investigate potential differences between four
treatment intervention groups in the adherence to treatment with Differin® Gel, 0.1%.
Differin is approved by the Food and Drug Administration (FDA) to treat acne.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: Phase 4

First Posted: June 09, 2008 | Last Updated: February 10, 2017

Study Completion Date: October 01, 2009

Learn More

Optical Clearing of the Skin in Conjunction With Laser Treatments


The research hypothesis is that topical application of a mixture of pre-polymers of
polypropylene glycol and polyethylene glycol (an optical clearing agent) will reduce skin
light scattering, increasing the amount of light reaching the target for diagnostic as well
as therapeutic purposes.

Condition: Acne, Hypertrichosis, Nevus of Ota, Port Wine Stain, Scars, Sebaceous Gland Diseases, Tattoos | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: December 18, 2007 | Last Updated: February 08, 2017

Study Completion Date: July 01, 2008

Learn More

Effect of Multiple Subcisions on Rolling Acne Scars


The purpose of this study is to find out whether the use of multiple subcisions over several
visits will improve the appearance of rolling acne scars compared to no treatment.

This study was a pilot study designed to determine feasibility of this procedure.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Active, not recruiting | Phase: N/A

First Posted: August 12, 2014 | Last Updated: February 07, 2017

Study Completion Date: December 01, 2017

Learn More

Apremilast in the Treatment of Moderate to Severe Acne


Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the
population, especially teenagers, although adult acne is a significant problem for 3-6 % of
adult men and 5-12% of adult women. Although acne is not a life-threatening disease, it
produces significant psychological disturbances and permanent skin scars.

A novel anti-inflammatory, not antibiotic drug may be an excellent alternative for the
treatment of moderate to severe acne. Apremilast has been shown to inhibit the production of
tumor necrosis factor (TNF)-alpha, IL-8 and neutrophil infiltration, all of which are
elevated in inflammatory acne.

Our intention is to study Apremilast in the treatment of moderate to severe acne.

Condition: Acne | Minimum Age: 18 Years

Status: Terminated | Phase: Phase 2

First Posted: February 22, 2010 | Last Updated: February 01, 2017

Study Completion Date: October 01, 2010

Learn More

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel


This is an Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo
Controlled, Three Arm Clinical Study.

The main objective is to evaluate bioequivalence of Test formulation (Clindamycin Phosphate
1.2%/Benzoyl peroxide 5% gel) of Cadila Healthcare with Reference formulation (DUAC® Gel of
Stiefel Laboratories)in the ratio of 2:2:1 of Test drug, Reference drug and Placebo
respectively.

Total study duration will be for a period of 78 days which includes treatment duration of 77
days.

850 subjects will be enrolled (randomized)as per the inclusion and exclusion criteria
mentioned in the protocol.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: November 28, 2013 | Last Updated: February 01, 2017

Study Completion Date: September 28, 2016

Learn More

Impact of the M22-IPL Acne Filter on Acne Vulgaris


Up to 20 healthy subjects age 15-45 years old ,Skin Phototype I-V,Study will be conducted in
1 site.

Primary objectives is to evaluate the efficacy of IPL acne filter treatment for improvement
of acne vulgaris as assessed by lesion count.

Condition: Acne | Minimum Age: 15 Years

Status: Terminated | Phase: N/A

First Posted: July 01, 2014 | Last Updated: January 25, 2017

Study Completion Date: December 01, 2015

Learn More

A Novel Method to Improve Acne Outcomes


This is an investigator-blinded, prospective study of 20 subjects aged 13 through 18 with
mild to moderate acne. Study subjects will be randomized to an internet survey group, in
which an email link for a survey ascertaining the status of the subject's acne is sent
weekly, or to a control group. All study subjects will use benzoyl peroxide 5% gel, and
adherence and clinical improvement will be monitored over 12 weeks. The investigators
hypothesis is that subjects in the internet survey group will have improved adherence to the
study medication and clinical outcomes, because the weekly survey will remind subjects to use
their medication.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: N/A

First Posted: August 05, 2010 | Last Updated: January 24, 2017

Study Completion Date: August 01, 2010

Learn More

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne


Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative
for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a
combination product including these actives for the treatment of acne vulgaris.

You may be suitable to take part in this study because you have acne vulgaris on your face.
Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms,
legs, and back.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: July 07, 2008 | Last Updated: January 13, 2017

Study Completion Date: March 01, 2009

Learn More

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers


The study will assess safety and tolerability of different doses of topical gel containing a
new chemical entity, NVN1000, and the vehicle (gel without drug) applied to the face of
healthy volunteers with high counts of Propionibacterium acnes. The test product will be
applied once daily for 4 weeks. Exploratory measures include whether the topical product
decreases the amount of a bacteria associated with acne (P. acnes).

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: September 25, 2012 | Last Updated: January 03, 2017

Study Completion Date: November 01, 2012

Learn More

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris


This is a randomized, multi-center, double-blinded study in subjects with moderate to severe
acne vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2
concentrations of a topical drug in development or a vehicle. Subjects will be treated for up
to 12 weeks.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: September 10, 2014 | Last Updated: January 03, 2017

Study Completion Date: August 01, 2015

Learn More

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris


This is a 21 day, single-center, open-label pharmacokinetic, safety and tolerability study in
adolescents with moderate to severe acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 1

First Posted: June 09, 2016 | Last Updated: January 03, 2017

Study Completion Date: June 01, 2017

Learn More

Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction


The purpose of this study is to determine whether Artefill is safe and effective for the
correction of atrophic facial acne scars.

Condition: Atrophic Acne Scar | Minimum Age: 18 Years

Status: Completed | Phase: Phase 3

First Posted: March 15, 2012 | Last Updated: December 21, 2016

Study Completion Date: February 01, 2014

Learn More

P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne


This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel
group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: January 26, 2016 | Last Updated: December 20, 2016

Study Completion Date: October 01, 2017

Learn More

P3 Study in Acne Comparing Once Daily SB204 and Vehicle


This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel
group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: February 01, 2016 | Last Updated: December 20, 2016

Study Completion Date: October 01, 2017

Learn More

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris


Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the
treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: July 01, 2016 | Last Updated: December 19, 2016

Study Completion Date: December 01, 2016

Learn More

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris


This study will assess the safety and efficacy of dapsone gel versus vehicle control in
patients with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: October 28, 2013 | Last Updated: December 13, 2016

Study Completion Date: October 01, 2014

Learn More

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris


This study will assess the safety and efficacy of dapsone gel versus vehicle control in
patients with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: October 28, 2013 | Last Updated: December 13, 2016

Study Completion Date: October 01, 2014

Learn More

A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars


The purpose of this study is to compare the effectiveness of the ePrime fractional
radiofrequency system to the 1550-nm fractional photothermolysis system (Fraxel) in the
ability to improve acne scar appearance.

Condition: Cicatrix | Minimum Age: 18 Years

Status: Active, not recruiting | Phase: N/A

First Posted: October 15, 2013 | Last Updated: December 05, 2016

Study Completion Date: December 01, 2017

Learn More

A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris


A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser
(Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Withdrawn | Phase: Phase 4

First Posted: December 31, 2015 | Last Updated: December 05, 2016

Study Completion Date: April 01, 2016

Learn More

Study to Evaluate the Efficacy and Safety of 1.5 mg/kg/Day of Sarecycline vs Placebo in the Treatment of Acne Vulgaris


A Study to Evaluate the Efficacy and Safety Sarecycline in the Treatment of Acne Vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Withdrawn | Phase: Phase 3

First Posted: September 18, 2015 | Last Updated: December 05, 2016

Study Completion Date: December 01, 2016

Learn More

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301


The purpose of this study is to assess safety and efficacy of a new foam formulation of
tazarotene in subjects with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: November 19, 2009 | Last Updated: November 30, 2016

Study Completion Date: November 01, 2010

Learn More

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris


A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study
to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel,
0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide)
gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: January 05, 2016 | Last Updated: November 23, 2016

Study Completion Date: October 01, 2016

Learn More

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT


The purpose of this study is to see if the investigators can prevent or reduce the severity
of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
One topical agent is the dapsone gel and the other is a skin moisturizer. Dapsone gel is an
FDA approved medication that you apply to the face. It is commonly used to treat acne. Skin
moisturizers are recommended to patients who receive Cetuximab treatment. In addition to
these topical agents they will be given a pill to take once a day. This pill has already been
shown to help fight rashes from Cetuximab.

Condition: Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma | Minimum Age: 18 Years

Status: Completed | Phase: Phase 3

First Posted: August 26, 2013 | Last Updated: November 18, 2016

Study Completion Date: September 01, 2015

Learn More

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne


The primary objective of this study is to compare the efficacy and safety and tolerability of
ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: September 27, 2012 | Last Updated: November 11, 2016

Study Completion Date: July 01, 2013

Learn More

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris


To compare the safety and efficacy profiles of Tazarotene Cream, 0.1 % to the reference
listed drug Tazorac® (tazarotene) Cream, 0.1 % in order to demonstrate bioequivalence, and to
demonstrate superiority of the 2 active creams over that of the cream vehicle (placebo) in
the treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: March 19, 2014 | Last Updated: November 02, 2016

Study Completion Date: July 01, 2015

Learn More

Effects of Omega-3 Fatty Acid Supplementation in Acne Patients


60 patients receiving isotretinoin will be recruited from the UCLA acne specialty clinic.
Subjects will be randomized in a 1:1 ratio to receive placebo or omega-3 1200mg twice a day
for 24 weeks.

Condition: Acne | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 3

First Posted: January 07, 2013 | Last Updated: October 27, 2016

Study Completion Date: January 01, 2020

Learn More

Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris


To determine if Dapsone (Aczone) 7.5% gel is a safe and effective treatment for acne on the
trunk

Condition: Acne | Minimum Age: 12 Years

Status: Recruiting | Phase: Phase 4

First Posted: October 04, 2016 | Last Updated: October 24, 2016

Study Completion Date: November 01, 2017

Learn More

Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris


Safety and Efficacy of IDP-123 Lotion to Tazorac® (tazarotene) Cream, 0.1%, in the Treatment
of Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: October 11, 2016 | Last Updated: October 17, 2016

Study Completion Date: September 01, 2016

Learn More

Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne


This is a Randomized, Double-Blind, Controlled Study to evaluate the Safety and Efficacy of a
clindamycin / benzoyl peroxide gel in Subjects with Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: October 21, 2008 | Last Updated: October 11, 2016

Study Completion Date: September 01, 2009

Learn More

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne


Multi-center, single-blind, randomized, comparative, split-face study. The duration of the
study is 8 weeks. Commencing at baseline, subjects will apply once daily both clindamycin and
benzoyl peroxide gel and benzoyl peroxide/adapalene gel in a bilateral split-face fashion
(allocation to left and right side randomly assigned) for an initial 2 weeks. After visit 3,
subjects will commence application of clindamycin and benzoyl peroxide gel to the entire face
for an additional 6 weeks.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: August 20, 2009 | Last Updated: October 11, 2016

Study Completion Date: November 01, 2009

Learn More

Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris


Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant
metabolites after topical dermal application of IDP-121 lotion.

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 1

First Posted: July 06, 2016 | Last Updated: October 11, 2016

Study Completion Date: October 01, 2016

Learn More

Non-cutting Laser Therapy in the Treatment of Acne


The purpose of this research project is to study the effect of non-ablative (non-cutting)
laser therapy, a technique that uses laser energy to try to improve the appearance of the
skin. This type of laser treatment creates changes in a layer of the skin called the dermis
without causing an open wound in the skin. The use of non-ablative laser therapy, together
with application of a photo-sensitizer (substance that makes the skin more sensitive to
light), may improve the appearance of acne. The idea behind the photo-sensitizer is that it
is supposed to make the laser more effective than using just the laser alone. It is not yet
clear how much improvement can be seen with these treatments or exactly how the skin's
response causes these improvements. In this study, we are interested in learning how well
such a laser works to improve the symptoms of acne, as well as how much the photo-sensitizer
actually enhances the efficacy of the laser.

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Completed | Phase: Phase 2

First Posted: June 07, 2005 | Last Updated: August 22, 2016

Study Completion Date: November 01, 2008

Learn More

P3 Long Term Safety Study of Once Daily SB204 in Acne


This is a multi-center, open label long-term safety (LTS) study to be conducted in
approximately 600 subjects with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Active, not recruiting | Phase: Phase 3

First Posted: June 09, 2016 | Last Updated: August 02, 2016

Study Completion Date: October 01, 2017

Learn More

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris


The study hypothesis are based on the assumption that :

- CD0271 0.3%/CD1579 2.5% Gel provides superior clinical efficacy compared with Topical
Gel Vehicle in the overall population and in the subgroup of severe Subjects

- CD0271 0.3%/CD1579 2.5% Gel applied once daily for up to 12 weeks has an acceptable
safety and tolerability profile

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: June 14, 2013 | Last Updated: July 25, 2016

Study Completion Date: March 01, 2014

Learn More

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris


The purpose of this study is to compare the safety and efficacy of Perrigo's product to an
FDA approved product for the treatment acne vulgaris

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: July 31, 2015 | Last Updated: June 28, 2016

Study Completion Date: June 01, 2016

Learn More

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris


This study is designed to investigate the efficacy, safety and tolerability of MTC896 Gel in
subjects with acne. In this study, MTC896 Gel will be applied at 3 concentrations, twice
daily (bid) for 12 weeks and compared against a vehicle control.

Condition: Acne Vulgaris | Minimum Age: 16 Years

Status: Active, not recruiting | Phase: Phase 2

First Posted: March 17, 2015 | Last Updated: June 14, 2016

Study Completion Date: August 01, 2016

Learn More

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204


The study is a 4 way cross-over study in subjects with moderate to severe acne vulgaris who
will each receive SB204 4%, a supratherapeutic dose of SB204 (either 8 or 12%),
moxifloxacillin (positive control) and appropriate placebo to match. SB204 will be applied
topically to the upper back, upper chest, upper shoulders, and face.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: October 15, 2015 | Last Updated: June 09, 2016

Study Completion Date: April 01, 2016

Learn More

Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris


To find out the safety and effectiveness of dapsone.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: June 17, 2014 | Last Updated: May 25, 2016

Study Completion Date: November 01, 2014

Learn More

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris


The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared
to vehicle in patients with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: April 27, 2015 | Last Updated: May 16, 2016

Study Completion Date: April 01, 2016

Learn More

Timolol for the Treatment of Acne and Rosacea


This research is being done to determine the safety and tolerability of timolol in the
treatment of acne and rosacea. The investigators will also look for specific biomolecular
changes in acne or rosacea skin when it is exposed to timolol.

Timolol is approved by the Food and Drug Administration (FDA) for the treatment of glaucoma.
In dermatology, it has been used as a treatment to decrease the size of vascular (blood
vessel) malformations in infant skin. Timolol is not approved for use in acne or rosacea and
its use in this study is investigational.

Many people with rosacea have telangiectasias which are small, red dilated blood vessels on
the skin. They also suffer from flushing and acne-like lesions. Better treatments than those
currently available are desired.

Acne vulgaris, or acne, is another chronic inflammatory and very common skin disease that
affects about 8 out of 10 young adults and adolescents. Signs of acne include papules and
blackheads that are often called primary lesions because they represent an active form of the
disease. There are also secondary lesions that can form later; they are known as acne scars

Condition: Acne Vulgaris, Rosacea | Minimum Age: 18 Years

Status: Recruiting | Phase: Phase 1

First Posted: May 09, 2016 | Last Updated: May 12, 2016

Study Completion Date: March 01, 2020

Learn More

Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris


Acne vulgaris is a multifactorial, highly prevalent dermatologic condition that results in
visible lesions that can be quite disfiguring. Consequently, individuals with acne often
suffer from a wide range of psychological manifestations. Although there is consensus that
combination therapy is most effective in treating acne, researchers are constantly striving
to develop new treatment. Microcurrent therapy (MCT) is a non-invasive modality that has
successfully been used to promote wound healing and has been routinely used in aesthetics.
Use of MCT alone or in combination with current successful treatment such as blue light
phototherapy (BLP), may hold promise for acne treatment. The investigators propose to conduct
a small randomized control trial to determine the safety and preliminary efficacy of a novel
combination therapy to treat acne vulgaris. The investigators will recruit up to 60 males and
females and randomly assign them to one of 3 arms: 1) BLP; 2) MCT; and combination therapy
(BLP and MCT). The investigators will assess physiological parameters (number of acne
lesions, amount of sebum produced, degree of acne severity) and psychosocial factors
(dermatologic quality of life, social anxiety, depressive symptomatology, self-esteem).
Participants will complete a baseline assessment prior to initiating treatment and a
follow-up assessment at 4 weeks post termination of treatment. The investigators will conduct
intermediary assessments at weeks 3 and 5 and 1 week post termination of the treatment. The
investigators will use measures of central tendency to describe the sample and repeated
measures analysis of variance to compute the main and interaction effects.

Condition: Acne, Acne Vulgaris | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: April 21, 2015 | Last Updated: May 02, 2016

Study Completion Date: March 01, 2017

Learn More

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris


The goal of this study is to evaluate a complete topical acne regimen consisting of a
prescription acne medication (Epiduo® Gel) and an acne-specific cleanser (Cetaphil®
DermaControl™ Foam Wash) and moisturizer with sunscreen (Cetaphil® DermaControl™ Moisturizer
SPF 30) for safety, efficacy and patient satisfaction in student athletes with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: September 23, 2014 | Last Updated: April 20, 2016

Study Completion Date: February 01, 2015

Learn More

Microneedling Plus the Universal Peel For Acne Scarring


Acne is a prevalent disorder mostly witnessed in adolescents, but can be seen in adults.
Early treatment is imperative to reduce acne scarring which can appear with atrophic lesions,
and depending on the skin type, significant erythema (redness) or post-inflammatory
hyperpigmentation. A multi-modality approach to treatment is necessary when dealing with the
aforementioned types of lesions. Pharmacologic management is essential, but safe procedural
therapies are also necessary specifically with darker skinned individuals.

Percutaneous collagen induction therapy (PCIT) is a non-invasive treatment achieved by using
a micro-needling device, which is safe and effective in causing "micro-wounds" into the
dermis thereby initiating wound healing followed by collagen production. This is an ideal
treatment for acne scarring, re-texturizing of the skin, and hyperpigmentation for all skin
types . Currently there are very few studies evaluating the safety and efficacy of
microneedling and chemical peels in skin types III-VI.

The aim of this study is to evaluate the effects of the combination of microneedling and
chemical peel for the treatment of acne scars in skin types III-VI.

Condition: Acne Scarring | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: June 20, 2014 | Last Updated: February 18, 2016

Study Completion Date: December 01, 2015

Learn More

Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris


This is an open-label, multi-center study to be conducted in the United States. The study
will examine the change in lesion count in subjects using Epiduo® Gel Pump (once daily) in
conjunction with Cetaphil® DermaControl™ Foam Wash (twice daily) and Moisturizer SPF 30 (once
daily). Subjects with a clinical diagnosis of mild or moderate acne who are eligible for
treatment with Epiduo® in accordance with the currently approved product labeling and who
meet other inclusion/exclusion criteria are to be enrolled in the study and receive the study
products for 8 weeks. Efficacy and safety assessments include: complete lesion counts,
cutaneous irritation assessment, end of study treatment questionnaire, photographic
evaluation for oiliness, skin tone, and P Acnes, hydration assessment, barrier function
assessment, treatment compliance, and adverse event assessment.

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 4

First Posted: September 23, 2013 | Last Updated: February 17, 2016

Study Completion Date: March 01, 2014

Learn More

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris


This study is to determine the efficacy and safety of 12 week treatment with Differin® Gel
0.3% applied in the evening, in combination with Duac® (Clindamycin/Benzoyl Peroxide Gel)
applied in the morning, in Subjects with Acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: April 30, 2008 | Last Updated: February 16, 2016

Study Completion Date: August 01, 2008

Learn More

Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes


The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing
antibiotic sensitive and resistant strains of P acnes in vivo.

Condition: P Acnes Colonization | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: May 20, 2009 | Last Updated: February 16, 2016

Study Completion Date: July 01, 2009

Learn More

Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life


Acne vulgaris is a common problem in the adolescent community. Past research has shown that
acne affects teenager's self-esteem and mood. However, no research has evaluated the parent
perception of their teenager's acne in comparison to the severity of acne and the patient's
own reported quality of life. It is hypothesized that parents of teenagers underestimate how
much acne vulgaris affects their teenager's skin disease-related quality of life. Also that
teenager's perception of the severity of their acne is greater versus their parent's
perception. We believe that increased acne severity based on clinician assessment will
correlate with worse quality of life. Teenagers between 12 and 17 years old with a diagnosis
of acne by a pediatric dermatologist will be enrolled in this study. The study consists of 1
visit, questions regarding demographics, assessment of the teen's acne, the Skindex-Teen
quality of life survey (modified for parents), and 2 Likert scales will be completed. In
addition, the clinician will score the teen's acne using the standardized Investigator Global
Assessment tool. Statistical analysis will compare teen subject answers to the Skindex-Teen
with their parent's answers. Also analyzed will be the severity of acne and differences
between the clinician IGA score and Skindex-Teen responses

Condition: Acne, Quality of Life | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: April 16, 2013 | Last Updated: January 26, 2016

Study Completion Date: January 01, 2015

Learn More

Sleep, Circadian Rhythm & Skin Health


The purpose of this study is to explore the mechanisms behind how sleep quality may affect
skin aging, skin integrity and skin disease.

Condition: Acne, Eczema, Healthy, Psoriasis | Minimum Age: 18 Years

Status: Recruiting | Phase: N/A

First Posted: March 18, 2015 | Last Updated: December 03, 2015

Study Completion Date: December 01, 2020

Learn More

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris


Actavis has developed a generic formulation of clindamycin 1.2% and benzoyl peroxide 3.75%
gel. This study is designed to evaluate the safety and efficacy of this formulation in
subjects with Acne Vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: November 25, 2015 | Last Updated: November 25, 2015

Study Completion Date: November 01, 2015

Learn More

Study of the Use of Low Level Laser Therapy to Reduce Acne


The purpose of this study is to determine whether low level laser light therapy is effective
in the treatment of acne blemishes.

Condition: Acne | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: January 11, 2011 | Last Updated: November 07, 2015

Study Completion Date: June 01, 2010

Learn More

Ultherapy® for the Treatment of Acne Scars


This is a prospective, multi-site trial to be conducted at 2 clinical sites. Up to 20
subjects will receive study treatments. Following study treatments, follow-up visits will
occur at 60, 90 and 180 days from each subject's last study treatment.

Condition: Acne Scars, Atrophic Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: May 20, 2014 | Last Updated: October 19, 2015

Study Completion Date: October 01, 2015

Learn More

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris


The primary objective of this study is to evaluate the safety and efficacy of once-daily
topical application of CLS001 1%, 1.75% and 2.5% topical gel compared to vehicle topical gel
in subjects with inflammatory acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: February 18, 2014 | Last Updated: September 01, 2015

Study Completion Date: December 31, 1969

Learn More

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study


The pilot study will investigate whether combination treatment of Finacea 15% Gel and
Brimonidine 0.33% Gel could be more effective than Brimonidine 0.33% Gel monotherapy in
treating both the papules/pustules and erythema associated with rosacea.

Condition: Acne Rosacea | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: May 16, 2014 | Last Updated: August 28, 2015

Study Completion Date: February 01, 2015

Learn More

A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris


This study will evaluate the effect of dapsone gel in female subjects with skin of color
(Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: January 08, 2014 | Last Updated: August 11, 2015

Study Completion Date: September 01, 2014

Learn More

Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel


To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to
Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3
weeks in terms of local tolerability parameters (erythema, dryness, scaling,
stinging/burning) and preference.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: January 23, 2012 | Last Updated: August 10, 2015

Study Completion Date: May 01, 2012

Learn More

Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars


The purpose of this study is to assess treatment of facial acne scars using the 755nm
Alexandrite Laser with lens arrays.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: March 31, 2014 | Last Updated: July 29, 2015

Study Completion Date: May 01, 2015

Learn More

The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars


The purpose of this study to evaluate the SmartLipo Triplex laser system along with the
SideLaze800 hand piece in the treatment of Acne Scars.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: April 01, 2014 | Last Updated: July 29, 2015

Study Completion Date: February 01, 2015

Learn More

UVA1 Light for Scleroderma and Similar Conditions


The purpose of this investigation is to evaluate the effectiveness of high-dose UVA1
irradiation in the treatment of fibrosing conditions of the skin, e.g., keloid (a thick scar
from growth of fibrous tissue), scleroderma (deposits of fibrous tissue in the skin) and acne
keloidalis nuchae (keloids on the back of the neck or hairline) old burn scars, granuloma
annulare or other similar skin conditions. This UVA1 dosing schedule has been used
successfully in Germany for various skin diseases, such as the above mentioned scleroderma.

Condition: Acne Keloidalis Nuchae, Granuloma Annulare, Keloid, Scars, Scleroderma | Minimum Age: 10 Years

Status: Terminated | Phase: N/A

First Posted: May 18, 2007 | Last Updated: July 24, 2015

Study Completion Date: July 01, 2003

Learn More

Microdermabrasion for Acne


The purpose of this research project is to study the effect of micordermabrasion to try to
improve the appearance of facial acne. The microdermabrasion machine is a hand-held device
that directs pressurized aluminum oxide crystals at its target accompanied by a suction
device. It is not yet clear how much improvement can be seen with these treatments or exactly
how the skin's response causes these improvements. In this study, we are interested in
learning how well microdermabrasion works to improve the symptoms of acne.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: Phase 2

First Posted: July 21, 2006 | Last Updated: July 08, 2015

Study Completion Date: July 01, 2007

Learn More

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions


5 Day study to assess how quickly a topical acne product begins to work.

Condition: Skin Diseases | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: January 30, 2014 | Last Updated: May 14, 2015

Study Completion Date: May 01, 2014

Learn More

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications


This is a single-blind (blinded expert grader), randomized, half-face study being conducted
at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products,
antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral
side of the face will remain non-treated to serve as a control. Approximately 25-30 male and
female healthy subjects will be randomly assigned to each product

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: June 21, 2009 | Last Updated: May 01, 2015

Study Completion Date: July 01, 2009

Learn More

Infrared Non-Cutting Laser Therapy for Acne


The purpose of this research project is to study the effect of non-ablative (non-cutting)
laser therapy, a technique that uses laser energy to try to improve the appearance of the
skin. In this study, we are interested in learning how well such a laser works to improve the
symptoms of acne. The laser used in this particular study will be the CoolTouch II® laser,
manufactured by ICN Photonics, Inc., and has not been FDA-approved for the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: Phase 2/Phase 3

First Posted: May 11, 2005 | Last Updated: April 30, 2015

Study Completion Date: December 01, 2005

Learn More

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix


This research study will evaluate the effectiveness of high dose UVB light therapy in the
treatment of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn
scars, granuloma annulare or related conditions.

Condition: Acne Keloidalis, Granuloma Annulare, Keloid, Scars, Scleroderma, Localized | Minimum Age: 10 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: August 09, 2005 | Last Updated: April 30, 2015

Study Completion Date: January 01, 2009

Learn More

Safety and Efficacy of the Use of Botox on Acne


• To determine the safety and efficacy of Botox Treatment in subjects with mild to moderate
acne vulgaris defined by the Investigator's Global Assessment (IGA)

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Terminated | Phase: Phase 2

First Posted: September 30, 2008 | Last Updated: April 28, 2015

Study Completion Date: December 01, 2008

Learn More

Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris


This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne
vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 1

First Posted: August 14, 2014 | Last Updated: April 28, 2015

Study Completion Date: March 01, 2015

Learn More

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne


The purpose of this study is to determine the pharmacokinetic properties of topically applied
MTC896 Gel following application of 0.75% (w/w) MTC896 Gel once daily and twice daily and
1.5% (w/w) once daily over 4 weeks in the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: November 11, 2014 | Last Updated: April 16, 2015

Study Completion Date: January 01, 2015

Learn More

Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris


This study is a split face, paired-comparison, pilot study of 10 subjects. Participants in
this study will be patients seen at Children's Memorial Hospital, who are clinically
diagnosed with mild to moderate acne vulgaris. Participants will be recruited from the
clinic, as well as advertising and from previous Institutional Review Board (IRB) approved
acne studies housed in the Department of Dermatology. All subjects accrued from previous
studies have agreed to be contacted for further investigations. Subjects 13 to 35 years of
age with mild to moderate acne vulgaris symmetrical in appearance on both sides of the face,
and meeting inclusion criteria will be eligible to participate.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: N/A

First Posted: November 06, 2008 | Last Updated: April 10, 2015

Study Completion Date: January 01, 2009

Learn More

Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of P005672 in Treatment of Facial Acne Vulgaris


To evaluate the safety and effectiveness of 3 strengths of P005672 compared to placebo for
the treatment of moderate to severe facial acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: June 22, 2012 | Last Updated: April 09, 2015

Study Completion Date: January 01, 2013

Learn More

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris


This study will identify how much (if any) drug is absorbed from the skin of subjects with
acne vulgaris after topical application of SB204.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: June 12, 2014 | Last Updated: April 02, 2015

Study Completion Date: December 01, 2014

Learn More

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris


CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent
skin disorder. The purpose of this study is to compare the safety and efficacy of multiple
concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: June 27, 2012 | Last Updated: March 27, 2015

Study Completion Date: February 01, 2014

Learn More

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris


This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression
potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve
hours for two weeks, in subjects with acne vulgaris ages 12 years or older.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: April 11, 2013 | Last Updated: March 27, 2015

Study Completion Date: November 01, 2013

Learn More

Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars


The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the
treatment of atrophic acne scars.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: September 30, 2010 | Last Updated: March 09, 2015

Study Completion Date: September 01, 2012

Learn More

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel


This pilot study will explore if continuation of treatment of treatment with Aczone 5% gel
following combination treatment with with doxycycline and Aczone 5% gel can maintain
therapeutic response.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: June 21, 2013 | Last Updated: February 26, 2015

Study Completion Date: July 01, 2014

Learn More

Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone


This study will develop and evaluate the efficacy of an Internet-based education program
incorporating virtual coaching. For this study, the virtual coach will consist of online
videos aimed at providing acne education and promoting behaviors that support healthy skin.
The use of Web-based technologies and virtual coaching in acne-related patient education is
novel, and may significantly improve clinical outcomes and quality of life in acne patients.
We hypothesize that an interactive Internet-based education and counseling program will be
more effective than Internet-based education alone in improving clinical outcomes and quality
of life in acne patients.

Condition: Acne Vulgaris | Minimum Age: 13 Years

Status: Completed | Phase: N/A

First Posted: January 07, 2014 | Last Updated: February 26, 2015

Study Completion Date: July 01, 2014

Learn More

Musculoskeletal Effects of Isotretinoin During Acne Treatment in Pediatric Population


This is a prospective study, that will follow participants over their course of treatment on
Isotretinoin. All patients who are prescribed Isotretinoin for their acne treatment are
registered in iPLEDGE. The iPLEDGE program involves a set of steps that the patient,
physician and pharmacist must follow for the patient to take Isotretinoin. Patients will be
asked if they are willing to participate in this research study to determine musculoskeletal
changes in adolescents and young adults on systemic therapy using the highly sensitive
magnetic resonance (MR) imaging modality. In addition to the MRI, participants will be asked
if they are willing to give an extra sample of blood when their routine blood work is being
done for iPLEDGE. This blood sample will be used to determine if there are any effects of
isotretinoin on bone turnover markers.

Condition: Acne | Minimum Age: 12 Years

Status: Terminated | Phase: N/A

First Posted: August 21, 2009 | Last Updated: February 11, 2015

Study Completion Date: August 01, 2013

Learn More

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris


The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to
placebo for the treatment of moderate to severe acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: March 18, 2013 | Last Updated: January 26, 2015

Study Completion Date: December 31, 1969

Learn More

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.


The objectives of this study were to evaluate the efficacy and safety of drospirenone 3
mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with
moderate acne vulgaris during 6 treatment cycles.

Condition: Acne Vulgaris | Minimum Age: 14 Years

Status: Completed | Phase: Phase 3

First Posted: March 31, 2008 | Last Updated: December 29, 2014

Study Completion Date: July 01, 2004

Learn More

Evaluate Safety and Efficacy of an Oral Contraceptive (OC) Preparation Versus Placebo for 6 Treatment Cycles in Women With Moderate Acne


The objectives of this study were to evaluate the efficacy and safety of drospirenone 3
mg/ethinyl estradiol 0.02 mg (DRSP/EE) in comparison with placebo in female subjects with
moderate acne vulgaris during 6 treatment cycles

Condition: Acne Vulgaris | Minimum Age: 14 Years

Status: Completed | Phase: Phase 3

First Posted: April 09, 2008 | Last Updated: December 29, 2014

Study Completion Date: June 01, 2004

Learn More

Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne


This study will evaluate the effectiveness of Ultherapy for the treatment of facial acne.

Condition: Facial Acne | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: April 27, 2012 | Last Updated: December 03, 2014

Study Completion Date: July 01, 2014

Learn More

Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris


The goal of this study is to compare how efficient two different types of PDTs are when used
in combination with topical 5-ALA. The two types of PDT lights are Blu-U light and Candela
V-beam Pulse Dye Laser.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Withdrawn | Phase: N/A

First Posted: December 23, 2008 | Last Updated: December 02, 2014

Study Completion Date: February 01, 2014

Learn More

Bioequivalence Study of Generic Tretinoin 0.04% Microsphere Gel, 0.04% Retin-A Micro® and Placebo


The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear
Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: November 16, 2010 | Last Updated: November 17, 2014

Study Completion Date: October 01, 2010

Learn More

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris


The purpose of this study is to compare the safety and therapeutic equivalence of a generic
tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the
treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: October 14, 2014 | Last Updated: October 16, 2014

Study Completion Date: September 01, 2014

Learn More

Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo


The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear
Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: May 28, 2010 | Last Updated: October 15, 2014

Study Completion Date: April 01, 2010

Learn More

A Phase 1 Study Assessing Local Cutaneous Effects of SB204


In this study, color (erythema) and pH will be measured on 3 consecutive days after
application of 2 doses of SB204 to the cheeks of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: September 10, 2014 | Last Updated: September 24, 2014

Study Completion Date: September 01, 2014

Learn More

Collagen Injections for the Treatment of Acne Scars and Wrinkles


The purpose of this study is to find out if autologous (your own) fibroblast injections are
effective for the treatment of acne scars and wrinkles.

Condition: Acne Scars, Wrinkles | Minimum Age: 18 Years

Status: Terminated | Phase: Phase 1

First Posted: September 27, 2012 | Last Updated: September 03, 2014

Study Completion Date: June 01, 2013

Learn More

Topical ASC-J9 Cream for Acne


To evaluate the safety and efficacy of topical 0.1% and 0.025% ASC-J9 creams applied twice
daily for facial acne compared to vehicle control.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: February 02, 2011 | Last Updated: July 29, 2014

Study Completion Date: August 01, 2012

Learn More

Comparison Study of Topical Acne Regimens


The purpose of this study is to compare the effectiveness of two over the counter acne
products in subjects with moderate severity acne vulgaris. The two products being compared in
this study are Acne Free "Severe Acne Line" manufactured by University Medical Products, and
Proactiv® manufactured by Guthy-Renker.

Condition: Acne | Minimum Age: 13 Years

Status: Completed | Phase: Phase 4

First Posted: March 01, 2007 | Last Updated: June 23, 2014

Study Completion Date: February 01, 2008

Learn More

Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris


The purpose of this study is to determine the response of acne patients and healthy control
patients to the P. acnes bacteria. Half a tube of blood will be drawn from all participants
to determine whether or not they have antibodies to the P. acnes bacterium. Anywhere from 1
to 4 skin biopsies of acne pimples or normal control skin will be taken from all subjects for
further analysis in the lab to determine whether the inflammation in these pimples can be
reduced using anti-P.acnes antibodies.

Condition: Acne | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: August 21, 2013 | Last Updated: June 19, 2014

Study Completion Date: June 01, 2014

Learn More

Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne


The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a
marketed (generic) formulation of isotretinoin when both are administered twice daily with
meals.

Condition: Severe Nodular Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: September 09, 2009 | Last Updated: June 05, 2014

Study Completion Date: May 01, 2011

Learn More

Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris


This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in
subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via
subcutaneous injection. Subjects will receive injections at Days 0, 21, and 42 for a total of
3 injections. Study drug will be administered under close observation in a facility equipped
to handle medical emergencies. Subjects will not be discharged from the facility until at
least 1 hour following the injection or 1 hour after their vital signs have stabilized.
Safety will be assessed by pre- and post-treatment serial measurements of vital signs,
clinical laboratory assessments, and the recording of adverse clinical events.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: November 15, 2011 | Last Updated: June 05, 2014

Study Completion Date: December 01, 2012

Learn More

Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients


Open, prospective, randomized, single-centre study in patients with moderate to severe facial
acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4
inflammatory lesions, will be selected in acne-affected areas in the face. One area should be
identified on each cheek and one area should be identified on the forehead. The minimum
distance between the three areas should be at least 4 cm. For each patient the three areas
will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl
alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before
application of the Visonac cream. One of the areas cleaned with saline wipe will also be
occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo
fluorescence spectroscopy will be performed in the three areas before cream application, and
at 1h, 1.5h, 2h, 2.5h and 3 h after cream application. After the last fluorescence
spectroscopy reading, the cream should be wiped off and the patient should protect the three
areas from sunlight, prolonged, or intense light for 2 days.

The study was extended with additionally 8 patients to explore the photoactive porphyrin
levels over a 24 hour period:

The patients will clean their face with Cetaphil Gentle Skin Cleanser before cream
application. For each patient the three areas will be randomized to Visonac 80mg left on the
skin for 24 hours and Visonac (MAL8%) to be wiped of after 1 hour.

In vivo fluorescence spectroscopy will be performed at all three areas before cream
application, and at 2h, 3 h, 4h, 5h, 8h, 10h, 11h, 12h, 13h, 15 and 24h after cream
application. The exact time points may be adjusted based on the result from the previously
included patients. All patients will be instructed to protect the three areas from sunlight,
prolonged, or intense light for 2 days.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: July 08, 2010 | Last Updated: April 22, 2014

Study Completion Date: January 01, 2011

Learn More

Comparing OTC Acne Treatment to Prescription Regimen


This research is being done to find out the safety and efficacy of two acne creams, Effaclar
and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA
approved for the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: November 09, 2010 | Last Updated: March 24, 2014

Study Completion Date: October 01, 2011

Learn More

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris


The purpose of this study is to determine whether gevokizumab is effective in the treatment
of moderate to severe acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 17 Years

Status: Completed | Phase: Phase 2

First Posted: December 21, 2011 | Last Updated: March 03, 2014

Study Completion Date: June 01, 2013

Learn More

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne


Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female
patients with mild to moderate acne.

Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks.
Subjects will be required to return to the doctor's office for up to 5 visits.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: February 21, 2002 | Last Updated: February 23, 2014

Study Completion Date: July 01, 2002

Learn More

Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris


This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in
subjects with acne vulgaris following 28 days of dosing.

Condition: Acne Vulgaris | Minimum Age: 16 Years

Status: Completed | Phase: Phase 1

First Posted: January 18, 2013 | Last Updated: February 11, 2014

Study Completion Date: May 01, 2013

Learn More

Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.


The purpose of this study is to determine the tolerability of Cetaphil® DermaControl™ Foam
Wash and Moisturizer SPF 30 in pediatric subjects (7-11) with acne prone skin.

Condition: Acne Prone Skin | Minimum Age: 7 Years

Status: Completed | Phase: Phase 4

First Posted: July 01, 2013 | Last Updated: February 05, 2014

Study Completion Date: June 01, 2013

Learn More

Dose Range Study of CD5789 in Acne Vulgaris


To assess the efficacy and safety of different concentrations of CD5789 cream in subjects
with acne vulgaris for the purpose of dose identification.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: June 08, 2012 | Last Updated: January 14, 2014

Study Completion Date: September 01, 2013

Learn More

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers


This is a 3 day study to assess safety and tolerability of a new topical gel product, NVN1000
with and without the application of a commercially available moisturizer in approximately 15
healthy subjects. The test product will be applied to the forehead of healthy volunteers once
daily for 3 days. One group of subjects will have a moisturizer applied to the same area 15
minutes after the test gel was applied and one group of subjects will be treated with the gel
vehicle which does not contain the active product. The hypothesis is that the application of
moisturizer will not effect safety or local tolerability.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: December 18, 2012 | Last Updated: January 10, 2014

Study Completion Date: December 01, 2012

Learn More

A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel


This is a 2 week Phase 1 study of SB204 (NVN1000 Gel) in healthy adult volunteers with
elevated Propionibacterium acnes (P. acnes) counts. Subjects will apply NVN1000 4% Gel or
Vehicle Gel twice daily to their face. Assessments will include cutaneous tolerability,
safety, and P. acnes counts.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: April 29, 2013 | Last Updated: January 10, 2014

Study Completion Date: June 01, 2013

Learn More

Effects of PRK 124 Lotion in Acne Rosacea


The purpose of this open-label study is to determine the tolerance and efficacy of
twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the
signs and symptoms of mild to moderate facial rosacea.

Condition: Acne Rosacea | Minimum Age: 21 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: December 21, 2007 | Last Updated: December 16, 2013

Study Completion Date: February 01, 2009

Learn More

Fractional Resurfacing Device for Treatment of Acne Scarring


The purpose of this research study is to evaluate the safety and effectiveness of a new
investigational laser device for treatment of acne scarring, for improvement in the
appearance of surface texture and topography (recessed or uneven surfaces).

Condition: Acne, Scar | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: December 26, 2007 | Last Updated: December 13, 2013

Study Completion Date: July 01, 2008

Learn More

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris


This study is intended to evaluate the efficacy and safety of Visonac Photodynamic Therapy
(PDT) in patients with severe acne, score 4 on global IGA scale. The null hypothesis is that
Visonac PDT is equal to vehicle PDT against the alternative hypothesis that Visonac PDT is
different compared to vehicle PDT at week 12.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: May 03, 2011 | Last Updated: December 02, 2013

Study Completion Date: May 01, 2012

Learn More

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)


The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from
9 to 35 years old with Aktilite® CL512. Patients was randomized to Visonac or vehicle cream
without occlusion and red light(dose: 37J/cm2)

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 2

First Posted: July 02, 2009 | Last Updated: November 15, 2013

Study Completion Date: March 01, 2010

Learn More

"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"


The purpose of this study is to study the effects of topical Vitamin D cream (Calcipotriene,
also known as Dovonex) on the face and on the bacteria that cause acne. The information
gained from this study may lead to new treatments for acne. In this study, Calcipotriene will
be compared with a placebo, a cream that looks like Calcipotriene, but contains no active
ingredients.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Unknown status | Phase: Phase 2/Phase 3

First Posted: September 24, 2012 | Last Updated: October 18, 2013

Study Completion Date: December 01, 2014

Learn More

Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers


The purpose of this study is assess the safety and tolerability of lemuteporfin topical
solution (LTS) with exposure to red light (PDT), when applied to the backs of healthy
volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: April 10, 2013 | Last Updated: September 05, 2013

Study Completion Date: June 01, 2013

Learn More

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne


This multicenter study will be divided into 2 phases. The first phase will be an open label,
dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled,
parallel-group, dose-response phase. The second phase will only start if the first phase
succeeds in establishing well tolerated dose(s). Patients with moderate to severe acne
vulgaris in the face will be included.The results from part 2 has been presented in the
result section.

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Completed | Phase: Phase 2

First Posted: January 03, 2008 | Last Updated: August 07, 2013

Study Completion Date: September 01, 2008

Learn More

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring


The purpose of this study is to evaluate the safety profile and the treatment effect of
Isolagen TherapyTM and placebo when administered to facial acne scars.

Condition: Acne Scarring of the Face | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2/Phase 3

First Posted: March 19, 2008 | Last Updated: July 19, 2013

Study Completion Date: March 01, 2009

Learn More

Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris


In this multicenter study, patients with dark skin and acne vulgaris will be included. The
patients will receive treatment with MAL PDT and placebo PDT.

Condition: Acne Vulgaris | Minimum Age: 15 Years

Status: Completed | Phase: Phase 2

First Posted: May 05, 2008 | Last Updated: July 11, 2013

Study Completion Date: December 01, 2008

Learn More

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne


The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of
ANT-1207 in the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: February 09, 2011 | Last Updated: June 28, 2013

Study Completion Date: July 01, 2012

Learn More

Reduced Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne (i-PDT)


This research study aims to compare different methods for helping difficult to treat or
scarring (cystic) acne, ALA-PDT and i-PDT.

There is an investigational procedure called photodynamic therapy (ALA-PDT) that has been
reported to be very efficient for acne treatment since 2000. Photodynamic therapy (PDT) uses
a drug called ALA (aminolevulinic acid), which is marketed as Levulan®.

Levulan® is applied directly to facial/back acne. This is the way that it is usually applied.
Levulan® is left on the skin for three hours so the skin can absorb it. Next, the skin where
the Levulan® was applied is exposed to a red light for activation.

The sebaceous glands get obstructed and inflamed causing acne. ALA gets down under your skin
through the skin pores to where the glands are. PDT destroys the glands reducing the acne
lesion.

Levulan® is absorbed by normal skin surrounding the oil glands. Therefore, this procedure
also has some side effects. Some of the side effects include pain, burning sensation during
the procedure, and redness, tenderness, and swelling after the procedure.

At Massachusetts General Hospital's Wellman Center for Photomedicine, the investigators
developed another procedure called inhibitory-PDT (i-PDT) that is similar to ALA-PDT. i-PDT
is aimed at reducing the side-effects of ALA- PDT.

The difference between these two procedures is that i-PDT uses a light source that will
prevent Levulan® accumulation in the normal skin surface. The investigators would like to
find out if Levulan® will be placed only inside the sebaceous glands.

Condition: Acne Vulgaris | Minimum Age: 14 Years

Status: Unknown status | Phase: Phase 1

First Posted: October 05, 2011 | Last Updated: May 16, 2013

Study Completion Date: December 01, 2013

Learn More

Epidermal Delivery of Ani-Aging Ingredients


To assess the safety and efficacy of an ablative fractional, 2940-nm laser combined with the
US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne scars and
pigmented skin.

Condition: Acne Scars, Pigmentation, Wrinkles | Minimum Age: 35 Years

Status: Unknown status | Phase: N/A

First Posted: May 02, 2013 | Last Updated: May 02, 2013

Study Completion Date: September 01, 2013

Learn More

Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne


Acne vulgaris is a chronic inflammatory disorder of the skin in the pilosebaceous unit of the
hair follicle, associated with oil production. It is found across skin types and is present
in 85% of adolescents, representing a large affected population. Because of the universal
nature of the disease, 36.3% of acne patients come from backgrounds other than Caucasian.

The purpose of this study is to examine patient knowledge about acne in different populations
and to assess the effectiveness of a teaching intervention on acne knowledge. The
investigators aim is to better understand and subsequently reduce any potential health
disparities within the minority populations.

This project will evaluate differences in acne knowledge between different ethnic groups, and
the efficacy of an educational intervention. Subjects will first complete a survey evaluating
their knowledge of acne and how acne affects them psychosocially before an educational
intervention. Immediately following the intervention, the patient's knowledge of acne will be
evaluated again. Finally, two months after the intervention, a phone call will be made
evaluating their retention of the education materials and their quality of life related to
psychosocial effects of acne. Investigating this educational intervention and any current
disparities in acne education and understanding will better allow us to educate and treat
acne patients in the future.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: June 26, 2012 | Last Updated: April 29, 2013

Study Completion Date: November 01, 2012

Learn More

Treatment of Moderate to Severe Facial Acne Vulgaris


Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety
and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the
Investigator's Global Assessment (IGA) score and the absolute change from baseline in
inflammatory lesion count in patients with moderate to severe facial acne vulgaris.
Additionally, the absolute change from baseline in non-inflammatory and total lesions of the
active study medication to placebo will be evaluated.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: January 25, 2008 | Last Updated: April 15, 2013

Study Completion Date: December 01, 2008

Learn More

Epiduo Pediatric Acne Study


The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and
benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to
11 years of age with acne vulgaris.

Condition: Acne | Minimum Age: 9 Years

Status: Completed | Phase: Phase 4

First Posted: June 04, 2010 | Last Updated: April 04, 2013

Study Completion Date: August 01, 2011

Learn More

NdYag Laser for Acne Keloidalis Nuchae


Acne Keloidalis Nuchae (AKN) is a long standing hair follicle disease with bumps and scars on
the skin of the back of the head and neck. The purpose of this new study is to determine how
well a hair removal laser (NdYag Laser) works in treating AKN.

Condition: Acne Keloid, Acne Keloidalis, Acne Keloidalis Nuchae, AK, AKN, Dermatitis Papillaris Capillitii, Folliculitis Keloidalis Nuchae, Folliculitis Nuchae Scleroticans, Keloidal Folliculitis, Lichen Keloidalis Nuchae, NdYag Laser, Sycosis Framboesiformis, Sycosis Nuchae | Minimum Age: 18 Years

Status: Unknown status | Phase: N/A

First Posted: September 22, 2008 | Last Updated: March 27, 2013

Study Completion Date: December 01, 2013

Learn More

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris


The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for
16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry
Forward, Intent To Treat) in inflammatory lesion counts.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: March 21, 2011 | Last Updated: March 06, 2013

Study Completion Date: January 01, 2012

Learn More

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne


The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and
effective for treating acne on the trunk (the main part of the body that does not include the
arms, legs, and head).

Acne vulgaris is a very common skin disorder. It is caused when oil-producing skin glands
(sebaceous glands) become plugged. The plug can cause blackheads, whiteheads, pimples, and
cysts on the face, neck, upper chest, and upper back.

YAZ is a combination birth control pill. A "combination" pill means that it is made up of
more than one major ingredient. Nearly all birth control pills are made up of a combination
of estrogen and progestin hormones. Estrogens are steroid hormones produced by the ovaries
responsible for the typical female features. Progestins are steroid hormones produced by the
ovary and placenta responsible for making the uterus fit for pregnancy. YAZ also contains an
estrogen called ethinyl estradiol, and a progestin called drospirenone. People who develop
acne have sebaceous glands that are over-stimulated (that is, the sebaceous glands have
increased activity) by male sex hormones (androgens). The progestin in YAZ blocks the male
sex hormones (androgens) that cause acne.

The study drug being used in this study is called YAZ. It has been approved by the U.S. Food
and Drug Administration (FDA) to treat moderate acne in women who want an oral contraceptive
for birth control.

In this study, YAZ will be compared to a placebo for safety and effectiveness. A placebo
looks like the study drug but contains no active drug (like a sugar pill). We use placebos in
research studies to learn if the effects seen in research subjects are truly from the study
drug or from other reasons.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 3

First Posted: July 24, 2008 | Last Updated: January 29, 2013

Study Completion Date: April 01, 2012

Learn More

Effects of Acleara Needle Insert on Acne


This prospective, open-label study will be conducted in 15 healthy subjects per clinical site
ages 14 or older who meet the inclusion/exclusion criteria. Each subject may have up to 5
lesions treated on the face, chest or back with the Acleara insert. Subjects will receive up
to 3 follow up visits and evaluated for improvement in acne lesions and monitored for any
adverse events.

Condition: Acne Vulgaris | Minimum Age: 14 Years

Status: Completed | Phase: N/A

First Posted: August 29, 2012 | Last Updated: January 09, 2013

Study Completion Date: January 01, 2013

Learn More

A Study of a New Drug Treatment for Acne


A study to determine if three different doses of a new acne treatment are safe and better at
reducing facial acne than a treatment without active ingredient.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: March 30, 2011 | Last Updated: December 21, 2012

Study Completion Date: March 01, 2012

Learn More

Comparison of the RevLite Electro-optic Q-Switched Neodymium-doped Yttrium Aluminium Garnet (EO QS Nd:YAG) Laser to a Fractionated Laser System


The purpose of this study is to compare the results of treatment between the side of the face
treated with the RevLite Laser and the side of the face treated with a fractionated laser
system.

Condition: Acne Scars, Irregular Pigmentation, Photodamage | Minimum Age: 25 Years

Status: Completed | Phase: N/A

First Posted: August 06, 2009 | Last Updated: November 27, 2012

Study Completion Date: February 01, 2012

Learn More

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris


The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its
vehicle in the treatment of moderate-severe acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: November 11, 2010 | Last Updated: September 27, 2012

Study Completion Date: December 31, 1969

Learn More

Treatment of Acne Scarring With a Novel Procedure Combination


The primary objective of this study is to look at the efficacy of subdermal manipulation and
filler injection in the improvement of acne scar appearance.

Condition: Acne Scarring | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: July 31, 2007 | Last Updated: September 14, 2012

Study Completion Date: July 01, 2009

Learn More

A Pilot Study Testing the Efficacy of a Needling Device for the Treatment of Acne Scars


The primary objective of this study is to determine the efficacy of a needling device for
treatment of acne scars.

Condition: Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: September 09, 2009 | Last Updated: September 14, 2012

Study Completion Date: July 01, 2010

Learn More

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)


Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with
skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related
to acne vulgaris. However, it has not been clinically tested for this purpose. The current
study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris
and PIH.

Condition: Acne Vulgaris, Post Inflammatory Hyperpigmentation | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: December 23, 2009 | Last Updated: August 24, 2012

Study Completion Date: May 01, 2010

Learn More

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris


Comparison of the safety and efficacy of Tazarotene Cream 0.1% compared with Adapalene Gel
0.3% in treating moderate to severe facial acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Terminated | Phase: Phase 4

First Posted: January 22, 2009 | Last Updated: August 20, 2012

Study Completion Date: October 01, 2008

Learn More

Plant-based Dietary Intervention for Treatment of Acne


The purpose of this study is to determine if a low-fat, vegan diet affects the number of acne
lesions, acne severity, and acne extent.

Condition: Acne | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: May 11, 2009 | Last Updated: August 06, 2012

Study Completion Date: March 01, 2010

Learn More

Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles


To assess the safety and efficacy of the Pixel RF (fractional radio frequency) module in the
treatment of acne scars and wrinkles.

Condition: Acne Scars, Wrinkles | Minimum Age: 18 Years

Status: Unknown status | Phase: N/A

First Posted: July 13, 2012 | Last Updated: July 18, 2012

Study Completion Date: July 01, 2013

Learn More

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne


A study comparing the topical application of Aczone® plus Differin® versus Duac® plus
Differin® in patients with severe facial acne (facial acne vulgaris).

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: October 28, 2010 | Last Updated: June 25, 2012

Study Completion Date: June 01, 2011

Learn More

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris


The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in
treating patients with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: September 01, 2010 | Last Updated: June 20, 2012

Study Completion Date: December 01, 2011

Learn More

Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne


This study will determine if the use of the BEAM device reduces the signs and symptoms of
mild-to-moderate acne.

Condition: Acne | Minimum Age: 15 Years

Status: Completed | Phase: N/A

First Posted: July 13, 2010 | Last Updated: May 01, 2012

Study Completion Date: October 01, 2010

Learn More

Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate


Randomized, multi-center, open label, active-comparator study to compare the efficacy and
tolerability of Doryx Delayed Release Tablets to doxycycline hyclate in patients with
moderate to severe acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: March 07, 2008 | Last Updated: April 18, 2012

Study Completion Date: September 01, 2008

Learn More

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne


The purpose of the study is to evaluate the efficacy of CD07223 1.5% Gel and 0.5% gel in
reducing inflammatory, non-inflammatory, and total acne lesion counts after 6 weeks of twice
daily applications. The study will also evaluate the safety of the study products using
tolerance and adverse event data.

Condition: Acne | Minimum Age: 18 Years

Status: Completed | Phase: Phase 2

First Posted: April 19, 2010 | Last Updated: April 18, 2012

Study Completion Date: September 01, 2010

Learn More

Evaluation of a Photopneumatic System for the Treatment of Acne


The purpose of the study is to evaluate the safety and efficacy of a photopneumatic therapy
for the treatment of acne and concomitant symptoms associated with the disease, including
erythema.

Condition: Mild to Moderate Acne | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: December 08, 2010 | Last Updated: March 22, 2012

Study Completion Date: September 01, 2011

Learn More

The Development and Evaluation of an "E-Visit" Program for the Management of Acne


The purpose of this study is to test the efficacy, timeliness, and user satisfaction of an
online "E-Visit" application that uses store-and-forward technology for acne patients
requiring dermatologic care for their condition. Hypotheses:

1. That an "E-Visit" is an effective alternative to in-person clinic care for patients with
mild to severe facial acne.

2. That providers and patients will be satisfied with this model.

3. That mean wait times for new and return visits will be reduced through the "E-Visit"
model.

4. That this prototype for care will improve clinic workflow, offer additional patient
access, and allow urgent cases to be seen earlier.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: December 29, 2006 | Last Updated: March 14, 2012

Study Completion Date: December 01, 2007

Learn More

A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris


The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating
patients with acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: April 23, 2008 | Last Updated: February 16, 2012

Study Completion Date: September 01, 2009

Learn More

Evaluation of Irritation That Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face.


A study to compare the skin irritation potential of two marketed gels for acne treatment,
each applied to half of the face of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: July 10, 2008 | Last Updated: February 14, 2012

Study Completion Date: February 01, 2008

Learn More

A Study of Different Use Regimens Using Two Acne Treatments


A study to determine if using 2 acne products in the morning is as safe and efficacious as
using one product in the morning and one product in the evening.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: May 20, 2009 | Last Updated: February 14, 2012

Study Completion Date: September 01, 2009

Learn More

A Study of Acne Treatment in Children Ages 9 to 11


A study to determine if using Retin-A Micro 0.04% as facial acne treatment in patients ages 9
to 11 is safe and efficacious.

Condition: Acne Vulgaris | Minimum Age: 9 Years

Status: Completed | Phase: Phase 2

First Posted: May 20, 2009 | Last Updated: February 14, 2012

Study Completion Date: December 01, 2009

Learn More

Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face


A study to compare the skin irritation potential of two marketed gels for acne treatment,
each applied to half of the face of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: June 10, 2009 | Last Updated: February 14, 2012

Study Completion Date: May 01, 2009

Learn More

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face


A study to compare the skin irritation potential of two marketed gels for acne treatment,
each applied to half of the face of healthy volunteers.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: August 04, 2009 | Last Updated: February 14, 2012

Study Completion Date: October 01, 2009

Learn More

A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products


This study is to see if there's any difference in the amount of facial irritation when two
acne products are used together on one side of the face, compared to one acne treatment
product used alone on the other side of the face. All people participating in this trial will
be required to return to the same study center every weekday for two weeks for the
investigator to check for irritation on the face and to have the products applied - on
weekends they will have to put them on at home. If one side of the face is more irritated
than the other side, a picture will be taken as well.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: March 10, 2011 | Last Updated: February 14, 2012

Study Completion Date: January 01, 2011

Learn More

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris


The purpose of this study is to assess subjects' experiences using Adapalene BPO gel to treat
mild to moderate acne vulgaris using efficacy measurements, quality of life instruments, and
video diaries.

Condition: Acne Vulgaris | Minimum Age: 16 Years

Status: Completed | Phase: Phase 4

First Posted: September 24, 2010 | Last Updated: January 18, 2012

Study Completion Date: January 01, 2011

Learn More

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris


EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES,
L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris.
Actavis Mid-Atlantic LLC has developed a generic formulation of adapalene and benzoyl
peroxide topical gel 0.1%/2.5%,and the current study is designed to evaluate the safety and
efficacy of this formulation to determine if it is bioequivalent to EPIDUO™.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: N/A

First Posted: December 27, 2011 | Last Updated: December 28, 2011

Study Completion Date: December 01, 2011

Learn More

Combination Treatment for Moderate to Severe Acne


To determine if a combination of three currently approved acne products are safe and
effective for the treatment of moderate to severe acne

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: September 17, 2010 | Last Updated: November 28, 2011

Study Completion Date: July 01, 2011

Learn More

A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris


The purpose of this study is to evaluate if topical ASC-J9 cream is effective in treating
acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: August 31, 2007 | Last Updated: November 16, 2011

Study Completion Date: July 01, 2008

Learn More

Light Dose Ranging Study of Photodynamic Therapy (PDT) With Levulan + Blue Light Versus Vehicle + Blue Light in Severe Facial Acne


The purpose of this study is to determine and compare the safety and efficacy of multiple
broad area photodynamic therapy treatments with aminolevulinic acid (ALA-PDT) and vehicle
(VEH-PDT) in subjects with moderate to severe facial acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 2

First Posted: June 24, 2008 | Last Updated: October 20, 2011

Study Completion Date: July 01, 2008

Learn More

Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris


The purpose of this study is to evaluate whether Cerave lotion followed by Acanya Gel in the
morning in combination with Cerave lotion followed by Atralin gel in the evening is safe and
effective for the treatment of acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Unknown status | Phase: Phase 4

First Posted: October 05, 2011 | Last Updated: October 06, 2011

Study Completion Date: October 01, 2011

Learn More

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris


A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene
cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe
facial acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: January 30, 2009 | Last Updated: September 22, 2011

Study Completion Date: September 01, 2009

Learn More

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris


A 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tretinoin
gel 0.025% compared with tretinoin gel 0.025% monotherapy in treating moderate to severe
facial acne vulgaris

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: January 30, 2009 | Last Updated: September 22, 2011

Study Completion Date: August 01, 2009

Learn More

A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne


There are many different factors that cause acne. So combination treatment using different
medications that can address these different factors is commonly used to treat acne.
Fixed-dose combination clindamycin phosphate 1.2% and tretinoin 0.025% gel and benzoyl
peroxide 6% foaming cloths are both used to treat acne. This study will evaluate the use of
the medications when used together.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Unknown status | Phase: Phase 4

First Posted: August 12, 2011 | Last Updated: August 22, 2011

Study Completion Date: December 31, 1969

Learn More

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage


This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs
of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical
products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety)
utilizing the regimen of products.

Condition: Acne Vulgaris, Atopic Dermatitis, Rosacea, Seborrheic Dermatitis | Minimum Age: 25 Years

Status: Completed | Phase: Phase 2

First Posted: October 06, 2009 | Last Updated: June 06, 2011

Study Completion Date: January 01, 2010

Learn More

Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency


The purpose of this study is to gather more information about the safety of ACZONE Gel, 5% in
treating subjects with acne who have certain blood disorders.

ACZONE Gel, 5% is a prescription skin use (topical) medicine used to help treat acne in
people 12 years and older. ACZONE Gel, 5% has been studied in approximately 4000 people and
was shown to reduce the number of pimples and improve acne.

The active drug ingredient in ACZONE Gel, 5% is dapsone. People with blood disorders called
"G6PD deficiency", "methemoglobin reductase deficiency", and "hemoglobin M" have a higher
chance of side effects with dapsone.

G6PD is short for "glucose-6-phosphate dehydrogenase". It is an enzyme found in red blood
cells, which carry oxygen to all parts of the body. G6PD helps the red blood cells to
function normally. Some people have less G6PD in their red blood cells than the average
person. This is called G6PD deficiency.

Two treatments - ACZONE Gel, 5% and placebo - will be studied for comparison.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: October 21, 2005 | Last Updated: May 27, 2011

Study Completion Date: October 01, 2006

Learn More

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%


The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in
the treatment of Acne Vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: January 11, 2008 | Last Updated: March 21, 2011

Study Completion Date: November 01, 2008

Learn More

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%


The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in
the treatment of Acne Vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: January 11, 2008 | Last Updated: March 21, 2011

Study Completion Date: December 01, 2008

Learn More

A Novel Combination Oral Agent to Treat Acne Vulgaris


The purpose of this study is to evaluate a novel, combination product for the treatment of
acne vulgaris in females

Condition: ACNE VULGARIS | Minimum Age: 13 Years

Status: Unknown status | Phase: Phase 1/Phase 2

First Posted: February 16, 2011 | Last Updated: February 18, 2011

Study Completion Date: September 01, 2011

Learn More

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%


Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 4

First Posted: April 15, 2008 | Last Updated: January 19, 2011

Study Completion Date: November 01, 2008

Learn More

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris


The objective of this study was to evaluate the efficacy and safety of the test formulation
of adapalene gel 0.1% (PLIVA Research & Development Ltd.) as compared to the already marketed
formulation, Differin® (adapalene 0.1%) topical gel (Galderma Laboratories) in patients with
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 1

First Posted: August 13, 2010 | Last Updated: November 22, 2010

Study Completion Date: April 01, 2008

Learn More

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance


The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% /Benzoyl Peroxide
2.5% Gel compared to its Vehicle Gel as an acne maintenance treatment in Subjects previously
treated with Adapalene-BPO Gel or Adapalene-BPO Vehicle Gel both associated with Doxycycline
Hyclate 100 mg. The safety of the two investigational treatments will also be assessed.

Condition: Acne | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: May 28, 2008 | Last Updated: September 30, 2010

Study Completion Date: July 01, 2009

Learn More

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris


The investigators conducted a recent pilot study and found a strong positive correlation
between the consumption of 100% chocolate and acne exacerbation. However, this study had
limitations including the lack of placebo and the small sample size. Although studies have
been conducted assessing chocolate's effect on acne, no study has been done evaluating this
effect using chocolate with 100% cocoa content in a double blind placebo controlled fashion.
This study will analyze the difference in the number and type of acneiform lesions per
subject at the different time points (Day 4 and Day 7) compared to baseline in order to
increase the validity of the investigators results. In addition, the investigators will use
unsweetened cocoa powder,12 rather than chocolate candy, which contains higher quantities of
additive ingredients such as sugar and milk to avoid interference with the results and the
possibility to establish or not an association between the unsweetened cocoa and an effect on
acne.

Condition: Acne | Minimum Age: 18 Years

Status: Unknown status | Phase: N/A

First Posted: September 01, 2010 | Last Updated: September 01, 2010

Study Completion Date: March 01, 2011

Learn More

A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions


The purpose of this study is to find out how effective and safe an experimental ultrasound
device is for treating Acute Acne lesions.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: Phase 1

First Posted: July 09, 2010 | Last Updated: July 09, 2010

Study Completion Date: December 31, 1969

Learn More

Efficacy & Safety of Clindamycin and Tretinoin in Acne


The purpose of this study is ascertain the efficacy and safety of Clindamycin

Phosphate 1.2% and Tretinoin 0.025% in the treatment of Acne and Post

Inflammatory Hyperpigmentation in patients with skin of color.

Condition: Acne | Minimum Age: 12 Years

Status: Unknown status | Phase: Phase 4

First Posted: April 26, 2010 | Last Updated: May 19, 2010

Study Completion Date: April 01, 2010

Learn More

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris


The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% / Benzoyl Peroxide
(quoted as BPO) 2.5% Gel associated with Doxycycline Hyclate 100 mg Tablets compared to
Adapalene 0.1% /Benzoyl Peroxide 2.5% Vehicle Gel associated with Doxycycline Hyclate 100 mg
Tablets, in the treatment of severe acne vulgaris. The safety of the two treatment regimens
will also be evaluated.

Condition: Severe Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: May 28, 2008 | Last Updated: March 31, 2010

Study Completion Date: February 01, 2009

Learn More

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"


The purpose of this study is to determine whether an automated electronic reminder system
using text messages sent to patient's cell phones will help patients with acne be more
compliant with their topical medications and lead to an improvement of their acne.

Hypothesis: Automatically delivered electronic reminders in the form of text messages will
increase acne patient adherence to topical medications and consequently result in better
treatment outcome and higher patient satisfaction

Condition: Acne, Patient Compliance | Minimum Age: 12 Years

Status: Unknown status | Phase: N/A

First Posted: March 05, 2010 | Last Updated: March 05, 2010

Study Completion Date: August 01, 2010

Learn More

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris


This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.

The primary objective is to demonstrate the superiority in efficacy and assess safety of
Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene
Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide
Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12
weeks.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: January 11, 2007 | Last Updated: October 19, 2009

Study Completion Date: December 01, 2007

Learn More

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris


The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% /
Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in
Subjects with acne vulgaris after a 12-week treatment period.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: February 27, 2007 | Last Updated: August 05, 2008

Study Completion Date: October 01, 2007

Learn More

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris


12-week study to compare the efficacy and safety of a course of a twice daily treatment with
APS in the form of a lotion to its vehicle for the treatment of acne.

Condition: Acne Vulgaris | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: July 03, 2008 | Last Updated: July 11, 2008

Study Completion Date: December 31, 1969

Learn More

A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris


The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: April 15, 2008 | Last Updated: April 18, 2008

Study Completion Date: December 31, 1969

Learn More

A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris


The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with
acne vulgaris.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: April 15, 2008 | Last Updated: April 18, 2008

Study Completion Date: December 31, 1969

Learn More

Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne


To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1%
compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment
with Differin Gel, 0.1% followed by 6 weeks of treatment with Tazorac Cream

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: May 02, 2007 | Last Updated: March 28, 2008

Study Completion Date: September 01, 2006

Learn More

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%


The primary objective of this study is to investigate potential differences in treatment
adherence by teenagers among four interventions during treatment for acne.

Condition: Acne | Minimum Age: 13 Years

Status: Completed | Phase: Phase 4

First Posted: February 16, 2007 | Last Updated: March 27, 2008

Study Completion Date: June 01, 2007

Learn More

Safety and Efficacy of 1550nm Fractional Laser Treatment for Acne Scars in Fitzpatrick Type IV-VI Skin


Fractionated laser resurfacing is commonly used as a treatment for acne scarring in fair
skinned individuals. This study aims to test the efficacy and safety in darker skin types.
Patients are randomized to either the 10mJ 40mJ dosages and receive a total of five
treatments at 17% one month apart. Improvement is judged by a dermatologist as 0-25%, 25-50%,
50-75% or 75-100%. Side effects such as pigmentary abnormalities and pain are also evaluated.

Condition: Acne Scarring | Minimum Age: 18 Years

Status: Unknown status | Phase: N/A

First Posted: March 17, 2008 | Last Updated: March 21, 2008

Study Completion Date: September 01, 2008

Learn More

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris


This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
(safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
subject should remain the same during the study.

The primary objective is to demonstrate the superiority in efficacy and assess safety of
adapalene/benzoyl peroxide topical gel (adapalene/benzoyl peroxide gel) versus adapalene
topical gel, 0.1% (adapalene monad); benzoyl peroxide topical gel, 2.5% (benzoyl peroxide
monad) and topical gel vehicle (gel vehicle) in the treatment of acne vulgaris for up to 12
weeks.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: January 11, 2007 | Last Updated: September 10, 2007

Study Completion Date: July 01, 2007

Learn More

A Long-Term Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris


This is a multi-centre, open-label, non-comparative study to evaluate the long-term safety
and efficacy profile of Adapalene/Benzoyl Peroxide Gel.

Subjects are evaluated at Baseline, Weeks 1 and 2, and Months 1, 2, 4, 6, 8, 10, and 12.

Safety is evaluated by spontaneous reports of Adverse Events (AEs), the Local Tolerability
Assessment (Erythema, Scaling, Dryness, and Stinging/Burning), routine laboratory testing
(haematology, blood chemistry, and urinalysis), and monitoring of suspected sensitizations.
Efficacy is evaluated by analysis of Percent Change from Baseline in Inflammatory,
Noninflammatory, and Total Lesion Counts, and by the Subject’s Assessment of Acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 3

First Posted: March 08, 2007 | Last Updated: March 08, 2007

Study Completion Date: May 01, 2004

Learn More

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris


Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4)
is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4
is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase.
This study will test the safety and efficacy of zileuton in the treatment of facial acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Unknown status | Phase: Phase 2

First Posted: December 07, 2004 | Last Updated: February 05, 2007

Study Completion Date: May 01, 2005

Learn More

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®


Food allergy reactions cause various health disorders in sensitive people. These reactions
may be IgE-mediated,cell-mediated, energy disturbance-mediated, or a combination of the
three. Certain laboratory diagnostic procedures have been able to identify most IgE-mediated
or cell-mediated food reactions, but so far there is no test available in traditional
medicine to test the energy-mediated allergies and sensitivities. NAET® procedures have been
able to identify food substances triggering to energ disturbances in sensitive people causing
related health disorders. NAET uses one of the testing procedures called NST (Neuromuscular
sensitivity testing).The efficacy of NST-NAET to screen food sensitivity will be evaluated in
comparison with one of the well accepted, established, traditional medicine allergy testing
known as the IgE-specific antigen test.

Condition: Backache, Eczema, Acne, Hives and Itching of the Skin, Food Sensitivities, Headache, Indigestion | Minimum Age: 2 Years

Status: Completed | Phase: Phase 1/Phase 2

First Posted: January 10, 2006 | Last Updated: October 31, 2006

Study Completion Date: January 01, 2006

Learn More

Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser


Acne can be treated with a mid-infrared laser. We demonstrated safety and efficacy using
lower energy settings in order to make the treatments less painful

Condition: Acne, Acne Scars | Minimum Age: 18 Years

Status: Completed | Phase: N/A

First Posted: March 22, 2006 | Last Updated: March 22, 2006

Study Completion Date: February 01, 2006

Learn More

Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris


The purpose of the study is to compare the efficacy of three maintenance regimens (topical
tazarotene, oral minocycline, or both) in sustaining improvement in acne.

Condition: Acne Vulgaris | Minimum Age: 12 Years

Status: Completed | Phase: Phase 4

First Posted: September 01, 2005 | Last Updated: December 14, 2005

Study Completion Date: August 01, 2002

Learn More

Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea


The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg
Tablets, taken twice daily is effective in reducing the red and white heads and overall
redness associated with rosacea.

Condition: Acne Rosacea | Minimum Age: 18 Years

Status: Completed | Phase: Phase 3

First Posted: July 19, 2002 | Last Updated: June 23, 2005

Study Completion Date: December 31, 1969

Learn More